**2020 Report of Verified Case of Tuberculosis (RVCT)**

**Instruction Manual**

**January 2020**

**Contents**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | | | **Page** |
| **Introduction** | | | | **1** |
| **Overview** | | | | **6** |
| **What is New** | | | | **8** |
| **RVCT Sections and Questions** | **Revision Status** | | | **Page** |
| **New** | **Revised** | **No Change** |
| **Administrative Information** | | | | |
| **01 – Date Reported** |  |  | **X** | **10** |
| **02 – Date Counted** |  | **X** |  | **11** |
| **03 – State Case Number** |  |  | **X** | **12** |
| **04 – Local Case Number** |  |  | **X** | **13** |
| **05 – Case Already Counted by Another Reporting Area?** | **X** |  |  | **14** |
| **Demographics & Initial Evaluation** | | | | |
| **06 – Reporting Address** |  | **X** |  | **15** |
| **07 – Date of Birth** |  |  | **X** | **17** |
| **08 – Sex at Birth** |  | **X** |  | **18** |
| **09 – Ethnicity** |  | **X** |  | **19** |
| **10 – Race** |  | **X** |  | **20** |
| **11 –** **Nativity** | **X** |  |  | **22** |
| **12 – Country of Usual Residence** | **X** |  |  | **24** |
| **13 – Status at TB Diagnosis** |  | **X** |  | **25** |
| **14 – Initial Reason Evaluated for TB** |  | **X** |  | **26** |
| **Risk Factors** | | | | |
| **15 – Occupation and Industry** | **X** |  |  | **27** |
| **16 – Other Risk Factors** | **X** |  |  | **30** |
| **17 – If Resident of Correctional Facility at Diagnostic Evaluation, Type  of Facility?** |  |  | **X** | **33** |
| **18 – If Resident of Long-Term Care Facility at Diagnostic Evaluation, Type of Facility?** |  |  | **X** | **34** |
| **19 – Current Smoking Status at Diagnostic Evaluation** | **X** |  |  | **36** |
| **20 – Lived outside of the United States for >2 months (uninterrupted)?** |  | **X** |  | **37** |
| **Diagnostic Testing (Other than Drug Susceptibility Testing [DST])** | | | | |
| **21 – Tuberculin Skin Test and All Non-DST TB Laboratory Test Results** |  | **X** |  | **38** |
| **22 – Chest Radiograph or Other Imaging Study Results** |  | **X** |  | **42** |
| **Clinical History and Findings** | | | | |
| **23 – Has the Patient been Previously Diagnosed with TB Disease or LTBI?** |  | **X** |  | **44** |
| **24 – Date of Illness Onset/Symptom Start Date** | **X** |  |  | **45** |
| **25 – Site of TB Disease** |  | **X** |  | **46** |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Epidemiologic Investigation** | | | | |
| **26 – Case Meets Binational Reporting Criteria?** | **X** |  |  | **47** |
| **27 – Case Identified During a Contact Investigation of Another Case?** | **X** |  |  | **49** |
| **28 – Contact Investigation Conducted for This Case?** | **X** |  |  | **50** |
| **29 – Complete Table Below for All Known TB and LTBI Cases Epidemiologically Linked to this Case** | **X** |  |  | **51** |
| **Initial Treatment Information** | | | | |
| **30 – Date Therapy Started** |  |  | **X** | **52** |
| **31 – Initial Drug Regimen** |  | **X** |  | **53** |
| **32 – If Initial Drug Regimen Not RIPE/HRZE (Isoniazid, Rifampin, Pyrazinamide, and Ethambutol), Why Not?** | **X** |  |  | **54** |
| **Genotyping and Drug Susceptibility Testing** | | | | |
| **33 – Isolate Submitted for Genotyping?** |  |  | **X** | **55** |
| **34 – Was Phenotypic/Growth-Based Drug Susceptibility Testing Done?** |  | **X** |  | **56** |
| **35 – Was Genotypic/Molecular Drug Susceptibility Testing Done?** | **X** |  |  | **57** |
| **36 – Was the Patient Treated as an MDR TB Case (Regardless of DST Results)?** | **X** |  |  | **59** |
| **Case Outcome** | | | | |
| **37 – Sputum Culture Conversion Documented?** |  |  | **X** | **60** |
| **38 – Moved During Therapy?** |  | **X** |  | **62** |
| **39 – Date Therapy Stopped** |  |  | **X** | **64** |
| **40 – Reason Therapy Stopped or Never Started?** |  | **X** |  | **65** |
| **41 – Reason TB Disease Therapy Extended >12 Months, if applicable** |  | **X** |  | **66** |
| **42 – Treatment Administration** |  | **X** |  | **67** |
| **43 – Did the Patient Die (either before diagnosis or at any time while being followed by TB program)?** | **X** |  |  | **68** |
| **Appendices** | | | | |
| **Appendix A – Tuberculosis Case Definition for Public Health Surveillance** | | | | **71** |
| **Appendix B – Recommendations for Reporting and Counting Tuberculosis Cases** | | | | **72** |
| **Appendix C – Reporting Areas Codes** | | | | **76** |
| **Appendix D – Anti-TB Drug Names and Genes Associated with Drug Resistance** | | | | **77** |
| **Appendix E – RVCT Molecular DST Report** | | | | **78** |
| **Appendix F – RVCT Molecular DST Report Examples** | | | | **81** |
| **Appendix G – MDR TB Supplemental Surveillance Form** | | | | **92** |
| **Appendix H – Instructions for MDR TB Supplemental Surveillance Form** | | | | **94** |
| **Appendix I – Anatomic Codes** | | | | **102** |
| **Appendix J – Glossary** | | | | **108** |

**Introduction**

**Background**

Tuberculosis (TB) is a nationally notifiable disease, and reporting is mandated in all states. In 1953, a national surveillance system was established to collect information on new cases of active TB disease. Since 1985, all states have been reporting TB cases to the Centers for Disease Control and Prevention (CDC) using the Report of Verified Case of Tuberculosis (RVCT), the national TB surveillance form. Data are collected by state and local TB programs and submitted electronically to CDC, Division of Tuberculosis Elimination (DTBE). These data are used to monitor national TB trends, identify priority needs, and create the DTBE annual surveillance report, *Reported Tuberculosis in the United States.*

To control and eventually eliminate TB, state and local TB control programs must be able to monitor trends in TB disease in high-risk populations, as well as identify new patterns of disease and possible outbreaks. The last major revision of the RVCT was completed in 2009. Since 2016, members of a DTBE-sponsored workgroup consisting of nearly 30 public health professionals from 15 TB control programs, DTBE, and the National TB Controllers Association (NTCA) have been working to revise the RVCT. Modifications to the RVCT data collection now accommodate the changing epidemiology of TB in terms of risk factors, new drug treatments, and enhanced laboratory capacity for diagnostic tests.

|  |
| --- |
| **Note:** A case of TB is defined as an episode of TB disease in a person meeting the laboratory or clinical criteria for TB as defined in Appendix A – Tuberculosis Case Definition for Public Health Surveillance. |

**Tuberculosis Surveillance Data**

Some states may use a modified version of the 2020 RVCT or a data collection tool that is unique to their jurisdiction. These forms are used to collect the same data contained in the 2020 RVCT. However, just as the actual 2020 RVCT form is not sent to CDC, neither are any locally defined variables or additional data. CDC should never receive directly identifying information (e.g., names) of persons with TB for inclusion in the TB surveillance dataset. CDC does receive certain indirect identifiers (e.g., date of birth); these data are protected using strict data security standards as well as an Assurance of Confidentiality. Locally assigned numbers and characters are used for case identification and are included in **State and Local Case Numbers** (items 3 & 4) for use by CDC to identify cases when communicating with state or local agencies.

**Impact of RVCT Data**

The 2020 RVCT will assist TB control programs in gathering accurate and useful data. The additions and changes made to the variables of the 2020 RVCT will enable programs to capture data that are more inclusive of a variety of risk factors. These additional data will be essential to efficient and effective TB program management. The following table illustrates how the 2020 RVCT data can improve TB programs, and the negative effect of using inaccurate or incomplete data.

**Impact of 2020 RVCT Data**

|  |  |  |
| --- | --- | --- |
| **Benefits of RVCT Data** |  | **Negative effects of Inaccurate, Incomplete, or Unknown RVCT Data** |
| * Increased ability to assess program performance, completeness of data collection, and accuracy of reporting * Improved data for program planning and policy development (e.g., personnel, resources, funding) * Facilitation of patient services (e.g., quality of care, continuity of care, sharing of accurate information with patient and health facilities) |  | * Inaccurate follow-up of services to patients * Inadequate resources (e.g., funding, staff, facilities, drugs, and supplies) * Inaccurate evaluation and policy development * Misrepresentation of the public health burden of TB * Inability to measure TB program indicators that are based on surveillance data |

**Quality Assurance**

Assuring data completeness and quality is encouraged for all case reporting. Each reporting area should develop its own policy or procedure for reviewing and updating incomplete or incorrect data. These procedures should ensure that the data are collected and entered in the surveillance system accurately.

Although health departments share TB surveillance data with CDC, the responsibility and authority for TB surveillance rests with the health department. States vary in the structure and organization of their surveillance systems. As with any reportable disease, the completeness of TB reporting reflects how actively health departments solicit case report information. Historically, disease surveillance systems have been categorized as passive or active.

**Passive surveillance**

Health departments passively receive case reports from health care providers, depending on the health care providers to know and comply with reporting requirements.

**Active surveillance**

Health departments actively contact and interact with health care facilities or individual providers to stimulate disease reporting, sometimes directly assuming the primary responsibility of reporting cases from large or high-volume institutions.

CDC provides funding and technical assistance to health departments to support TB surveillance, and has encouraged them to take an active rather than passive approach to TB surveillance. Health departments are encouraged to identify local or private health care facilities that serve TB patients. Health departments are also encouraged to use other data sources to identify TB cases, including death certificates and laboratory reports.

**Overview**

The RVCT form is designed for the collection of information on cases of TB. The expanded RVCT was approved by the Office of Management and Budget (OMB) in 2019 to become effective January 2020.

|  |
| --- |
| **Note:** On the RVCT form and throughout this document, the term *state* is used to refer to the reporting jurisdiction, though not all jurisdictions are states. |

**Required and Recommended Uses of the 2020 RVCT**

Reporting of all verified cases to CDC is required by the cooperative agreement between CDC and state and local TB programs, regardless of whether the case is counted as part of the jurisdiction’s official TB case count (e.g., transfer cases already counted in another state or country).

Cases among persons who have been in the United States for <90 days (inclusive of the Report Date) should not be reported to CDC. TB disease diagnosed in patients <12 months after completion of treatment for a previous TB episode should not be reported as a new TB case; rather, the previous case report should be reopened and updated. All other countable and noncountable TB cases should be reported to CDC.

Noncountable TB cases help measure TB morbidity and case management burden, and reporting is required under the current cooperative agreement with reporting areas.

For the purposes of surveillance, a case of TB is defined based on laboratory or clinical evidence of active disease due to *M. tuberculosis* complex. For more information on the case definition of *M. tuberculosis* complex*,* see Appendix A – Tuberculosis Case Definition for Public Health Surveillance.

**2020 RVCT Form**

The 2020 RVCT form comprises two data collection reports:

1. Report of Verified Case of Tuberculosis: Complete this form for all patients with a verified case of TB.

2. Multidrug-resistant (MDR) TB surveillance form to be completed for all patients treated as MDR TB, regardless of DST results.

**2020 RVCT Items**

The revised RVCT form includes 43 items. The characteristics are varied; for example,

* Some items include one variable response
* Some items include more than one response (e.g., Items 5 and 6)
* Each item is delineated in its own box
* Some boxes are grouped together in larger boxes to visually and logically organize the space

Items are not necessarily listed in the order in which you might receive the information.

Data are entered on the RVCT form in several ways:

1. Writing in dates and other numbers (e.g., Items 1, 2, and 6)
2. Checking boxes (e.g., Items 8, 9, and 10)
   1. Select one
   2. Select all that apply
3. Writing in specific information (e.g., Items 11, 12)

**Unknown Dates**

There are several items that include dates. When entering dates on the form, use “99” for an unknown month or day, and “9999” for an unknown year. This may vary from what will be entered into a computer software program.

* 03 **99**  2020 – for March, unknown day, in 2020
* **99 99** 2020 – for unknown month and day in 2020
* 01 02 **9999** – for January 2, in a year that is unknown

|  |
| --- |
| **Note:** For each item that includes dates, read the instructions carefully about entering month, day, and year. Some items (e.g., **Date Reported**, Item 1) require that the actual month and year **always** need to be entered. For those items, the actual month (not 99) should be entered, and the actual year (not 9999) should be entered. |

**Pending vs. Unknown Information**

Leave the item blank if the information requested is pending. If a valid value cannot be determined and there is no check-box labeled Unknown, write the word *Unknown* inside the box that encloses the numbered item. CDC encourages active surveillance or collection of all applicable information; “unknown” information should be rare.

**Updating of the RVCT Form**

It may be necessary to update RVCT information if a case is reopened (e.g., a patient who had been lost to follow-up is found) or if previously unavailable information is obtained. When updated data are entered in an electronic record, the new data will automatically overwrite the old data.

**Additional Reporting Forms**

If the reporting area has its own TB case reporting forms and uses them to complete the RVCT variables, the staff should carefully review the RVCT variables and the instructions in this document to ensure that variables on the reporting area’s forms match those on the RVCT form.

**Data Entry and Security**

Data obtained from RVCT forms are entered in the software system designated by your jurisdiction and then transmitted electronically to CDC. Data security is an important responsibility shared by CDC, state, and local health departments. **Completed RVCT forms should never be sent to CDC.**

Access to the completed RVCT forms and data entry software should be restricted to individuals authorized to perform TB surveillance activities. Hard copies should be stored in a secured (locked) area. Access to the approved data entry software, local databases, and all other electronic surveillance files should be controlled using a local user identification (user ID) and password.

**Patient Confidentiality**

**Case numbers must not include personal identifiers.** Do not use names, initials, Social Security numbers, addresses, telephone numbers, or other information that could identify a patient.

Because of the sensitive nature of some of the data collected, CDC has provided an Assurance of Confidentiality for the surveillance system. Information collected on the RVCT that would permit identification of any individual will be held in confidence and will not be released without the consent of the individual, in accordance with sections 306 and 308(d) of the Public Health Service Act (42 U.S.C. 242k and 242m). Surveillance information reported to CDC is used for statistical and analytic summaries and for special investigations of TB epidemiology.

**What is New**

The RVCT form has items that are either new or revised from the previous RVCT that was published in 2009. To help orient previous RVCT users to the new items, the table of contents indicates which items are new or revised.

The RVCT **State Case Number** (item 3), also known as the RVCT number, remains standardized by adding a 4-digit code for year and a 2-character (alpha) code for state (or jurisdictional code for jurisdictions that are not states) to the 9-character alphanumeric local identifier, so that each state case number is unique for year and state. The State Case Number format is important to help when trying to identify a TB patient who has been transferred from one health jurisdiction (e.g., state) to another, and when trying to link TB cases (e.g., known contacts).

**New and Updated Items**

Eleven new items were added to improve data collection. These items are indicated in the table below.

**New Items on the Revised RVCT**

|  |  |
| --- | --- |
| **Item** | **Item Name** |
| **5** | **Case Already Counted by Another Reporting Area** |
| **11** | **Nativity** |
| **12** | **Country of Usual Residence** |
| **15** | **Occupation and Industry** |
| **16** | **Other Risk Factors** |
| **19** | **Current Smoking Status at Diagnostic Evaluation** |
| **24** | **Date of Illness Onset/Symptom Start Date** |
| **26** | **Case Meets Binational Reporting Criteria?** |
| **27** | **Case Identified During a Contact Investigation of Another Case?** |
| **28** | **Contact Investigation Conducted for This Case?** |
| **29** | **Complete Table Below for All Known TB and LTBI Cases Epidemiologically Linked to this Case** |
| **32** | **If Initial Drug Regimen Not RIPE/HRZE, Why Not?** |
| **35** | **Was Genotypic/Molecular Drug Susceptibility Testing Done?** |
| **36** | **Was Patient Treated as MDR TB Case (Regardless of DST Results)?** |
| **43** | **Did the Patient Die (Either before Diagnosis or at any time while being followed by TB Program)?** |

Other revised variables have been updated to reflect the changing field of TB epidemiology. Modified variables include several items where multiple test results may be entered such as responses for Tuberculin Skin Test and Non-DST Laboratory Test Results.

**Overview of the RVCT Instructions**

The RVCT instructions provide information on how to complete the 43 items on the RVCT form. The instructions provide details about each item, explain the nuances of how to answer the items, and provide examples to illustrate how to apply the instructions for entering data for a TB case.

## **Administrative Information**

1. **Date Reported**

|  |
| --- |
| **Primary Purpose:** The Date Reported is used to determine when the health department was first notified that a person may have TB. |

|  |  |  |
| --- | --- | --- |
|  | **Description** | **Comment** |
| **Month,** **day, and year** (e.g., 01/17/2020) | Date that a health department first **thought** that the patient may have TB.  ***or***  Date the health department received notification (verbal or written) from a health care provider that a patient might have TB**.** | If the day is unknown, enter 99 as the default value (e.g., 01/99/2020).  In this item, the **actual month and year always need to be entered.** Do **not** use 99 for the month or 9999 for the year. |

|  |
| --- |
| **Comment:** If the patient had a previous diagnosis of TB, Date Reported applies to the current TB episode. |

1. **Date Counted**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:**  Used to determine the approximate date that the reporting area reviewed the RVCT and determined that the case meets the official TB surveillance case definition. |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | ***MMWR* Week:** | The *Morbidity and Mortality Weekly Report* (*MMWR*)  week is the week of the epidemiologic year to when the state health department verified that the case meets the case definition for TB disease. | The *MMWR* week and year reported should represent the date when the reporting area verified that the case meets the TB surveillance case definition. This is the proxy for the TB case count date.  *MMWR* week is used to support public health reporting in the *MMWR* weekly morbidity tables and the annual *Summary of Notifiable Diseases, United States*.  *MMWR* year is used to determine the year in which the case is included for the purposes of determining TB case counts and incidence rates. | | ***MMWR* Year:** | *MMWR* year is the epidemiologic year to which a Nationally Notifiable Diseases Surveillance System case report is assigned. |  |  | | --- | | **\***For more info on *MMWR* weeks see links below  <https://wwwn.cdc.gov/nndss/downloads.html>  <https://wwwn.cdc.gov/nndss/document/MMWR_Week_overview.pdf> | |

1. **State Case Number**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** Used to uniquely identify case reports to facilitate communication between reporting areas and CDC. |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Year** | Year Reported is the year when the case was reported (e.g., 2020). | This year should correspond to the Report Date, which is not necessarily the same as the *MMWR* Year. | | **State** | State Code indicates the two-letter postal code of the state reporting this case, e.g., GA for Georgia (see Appendix C, Reporting Area Codes). | The term *state* is used to refer to the reporting area, though not all reporting jurisdictions are states (e.g., New York City). | | **Number** | Nine-character string unique within the reporting area. | This string can contain letters or numbers and is assigned by the reporting area. |   **Comment: Case Numbers**  **Year + State + Number = State Case Number**  A State Case Number may not be assigned to more than one case during a calendar year.   |  | | --- | | **Note:**  The State Case Number is the official identification number for the case. If additional communication about a record is required between CDC and a reporting area, this number is used to identify the record. The State Case Number is also commonly known as the RVCT number.  **Case numbers must not include personal identifiers**. To maintain patient confidentiality, do not use names (either patient or provider), initials, Social Security numbers, addresses, telephone numbers, or other information that could directly identify a patient as part of the State Case Number. State Case Numbers are transmitted to CDC and therefore must not include personal identifying information. | |

1. **Local Case Number**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:**  Used to uniquely identify case reports to facilitate communication between local health departments, reporting areas, and CDC. |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Year** | Year Reported is the year when the case was reported (e.g., 2020). | This year should correspond to the Report Date, which is not necessarily the same as the *MMWR* Year. | | **State** | State Code indicates the 2-letter postal code of the state reporting this case, e.g., GA for Georgia (see Appendix C, Reporting Area Codes). | The term *state* is used to refer to the reporting area, though not all reporting jurisdictions are states (e.g. New York City). | | **Number** | Nine-character string unique within the local program’s registry. | This string can contain letters or numbers and is assigned by the local program. |  |  | | --- | | **Note:** A Local Case number may not be assigned to more than one case during a calendar year. | |

**Comment: Case Numbers**

Local Case Number is the same as City/County Case Number.

A single case may be assigned identical City/County Case and State Case Numbers.

1. **Case Already Counted by Another Reporting Area?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** TB cases may be reported by multiple reporting areas in the event that the patient moved between reporting areas while under care for a TB episode; however, to avoid double-counting the case, it is important that only one reporting area officially “count” the case. This question helps to determine whether the case report should be considered “countable” for incidence calculations. |  |  |  |  | | --- | --- | --- | | **Option**  ***(select one)*** | **Description** | **Comment** | | **Yes, another U.S. reporting area (Specify state case number from other area.)** | The case has already been counted by another U.S. reporting area such as another state (e.g., transfer in).  Under Specify, enter the state case number assigned to the case by the other reporting area. | Reporting jurisdictions are encouraged to work collaboratively to resolve disagreements about which reporting area should count a case. If necessary, CDC will arbitrate this determination.  See Note (below) for definition of U.S. reporting areas. | | **Yes, another country (Specify country)** | TB case counted by another  country that is not a U.S. reporting area.  Under Specify, enter the country where TB treatment was initiated. | It may be difficult to verify whether a case has been counted in another country. If confirmation that the case was counted cannot be obtained, consider the case to have been counted in the other country if the diagnostic evaluation was completed and the patient was prescribed anti-TB medications before arriving in the United States. | | **No** | Case was **not** counted by another reporting area. |  |  |  | | --- | | **Note: U.S. Reporting Areas**  U.S. reporting areas include the 50 United States, the District of Columbia, New York City (separate from New York State), five U.S. Territories (i.e., Puerto Rico, American Samoa, Guam, Commonwealth of the Northern Mariana Islands, U.S. Virgin Islands), and three freely associated states (Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau). These freely associated states are independent countries but are considered U.S. reporting areas for TB surveillance purposes. | |

**Demographics And initial Evaluation**

1. **Reporting Address**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To document the approximate location of the patient’s residence for the purpose of geographic analyses and correct assignment of the case to a public health jurisdiction. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | **Guidelines to Determine Reporting Address**   |  |  |  |  | | --- | --- | --- | --- | |  | **Patient Scenarios** | **How to Count** | **Reporting Address** | | **Specific Populations** (these groups supersede Specific Locations) | Migrant, immigrant (i.e., resident alien living in the United States), U.S. military personnel, and other persons residing in a community, even if the patient doesn’t consider that community to be “home.” | Count in the reporting area in which he/she lived at the time that the TB diagnostic evaluation was initiated | Enter city, county, ZIP Code, and census tract of the location where the patient was living when diagnostic evaluation was initiated. | | Homeless or does not have a fixed residence | Count in the reporting area in which the patient was living at the time that the TB diagnostic evaluation was initiated (e.g., the shelter or area in which the patient was living) | Enter city, county, ZIP Code, and census tract of the location where the patient was living when diagnostic evaluation was initiated. | | Resident of correctional facility at time of TB diagnosis | Count in the reporting area of the correctional facility the patient resided in located at the time that the TB diagnostic evaluation was initiated | Enter city, county, and ZIP Code, and census tract of the correctional facility where the patient was living when diagnostic evaluation was initiated. | | Resident of long-term care facility at time of TB diagnosis | Count in the reporting area of the long-term care facility the patient resided in at the time that the TB diagnostic evaluation was performed or initiated | Enter city, county, and ZIP Code, and census tract of the long-term care facility where the patient was living when diagnostic evaluation was initiated. | | **Specific Locations** | Diagnostic evaluation is initiated in the community the patient considers home. | Count in the case count for that reporting area. | Enter city, county, ZIP Code, and census tract of the location where the patient was living when diagnostic evaluation was initiated. | | Diagnostic evaluation is initiated in a community the patient is visiting or temporarily living for short-term work or study, and the patient will return home to complete treatment. | Count in case count of the patient’s home reporting area, if the patient’s home is in a U.S. reporting area. | Enter city, county, ZIP Code, and census tract of the patient’s usual residence. | | Diagnostic evaluation is initiated in a community the patient is visiting, and the patient completes treatment in the same reporting area (i.e., does not return home). | Count in case count of the reporting area where the patient was staying at the time that the TB diagnostic evaluation was initiated. | Enter city, county, ZIP Code, and census tract of where the patient was staying when diagnostic evaluation was initiated. |  |  | | --- | | **Note:** Report GEOID to the level of census tract (11 digits). Some surveillance data systems might have the capability to automatically geocode the patient’s address. When manual geocoding is required, use of the [U.S. Census Geocoder](https://geocoding.geo.census.gov/) is recommended. If the patient’s residence does not have a conventional street address, use the following instructions to geocode the patient’s residence using geographic coordinates: For patients whose residence does not have a street address for use in the U.S. Census Geocoder (e.g., some Native American reservations, U.S. territories), the patient’s residence can still be geocoded based on the geographic coordinates of the residence. The following instructions are for Google Maps; however, any mapping application can be used to obtain the latitude and longitude coordinates to enter into the geocoder application:   1. Find the physical location of the patient’s residence and display this location on the map within your web browser. 2. Hover your pointer over the approximate location (zoom in on the map as close as possible for maximum accuracy) of the patient’s residence and right-click to display the context menu. 3. Select “What’s Here?” from the context menu to pop up an information box at the bottom of the window that includes the location’s latitude and longitude coordinates. 4. Go to the U.S. Census Geocoder [Geographic Coordinates search page](https://geocoding.geo.census.gov/geocoder/geographies/coordinates?form) and copy and paste the exact coordinates from the Google Maps window into the “X” and “Y” fields, including any minus signs, then click the “Find” button. *IMPORTANT: The “X” field is for the longitude and the “Y” field is for the latitude.* 5. Scroll down to the “Census Tracts” section and copy the 11-digit GEOID from that section. This is the GEOID to enter on the RVCT.   *The freely associated states that are U.S. reporting areas (Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau) do not have U.S. census tracts. For cases in these reporting areas, leave the GEOID field blank.* | | |

1. **Date of Birth**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To calculate the patient’s age at the time of relevant events in the patient’s lifetime. |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Month,** **day, and year** (e.g., 04/26/1968) | Patient’s complete date of birth should be entered (i.e., month, day, *and* year). | If the patient is uncertain about his/her exact date of birth, provide as much specificity as possible.  If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 04/99/1968) or 99/99/1968.  In the month, day, and year of birth are unknown, enter 99/99/9999. | |

|  |
| --- |
| **Primary Purpose:** To establish the biological sex recorded for the patient at birth for evaluation of epidemiologic trends. |

1. **Sex at Birth**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  | | --- | --- | | **Option**  ***(select one)*** | **Description** | | **Male** | The biological sex recorded for the patient at birth was male. | | **Female** | The biological sex recorded for the patient at birth was female. | | **Unknown** | The biological sex recorded for the patient at birth is **not** known. |   **If recorded as female at birth:**  Pregnant at Time Diagnostic Evaluation was initiated?     |  |  | | --- | --- | | **Option**  *(****select one****)* | **Description** | | **Yes** | Patient was pregnant when TB diagnostic evaluation was performed or initiated. | | **No** | Patient was **not** pregnantwhen TB diagnostic evaluation was performed or initiated. | | **Unknown** | It is **not** known if patient was pregnant when TB diagnostic evaluation was performed or initiated. | |

1. **Ethnicity**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To establish the patient’s ethnicity for evaluation of epidemiologic trends associated with ethnicity. |  |  |  |  | | --- | --- | --- | | **Option**  ***(select one)*** | **Description** | **Comment** | | **Hispanic or Latino** | Patient considers himself or herself Cuban, Mexican, Puerto Rican, South or Central American, or of other Latin American culture or origin, regardless of race. | Some patients prefer the term “Spanish origin” to HispanicorLatino. | | **Not Hispanic or  Latino** | Patient does **not** consider himself or  herself Hispanic or Latino. |  | | **Unknown** | Patient’s ethnicity is **not** reported or unknown. |  |  |  | | --- | | **Note: Self-identity or self-reporting**  The response to this item should be based on the patient’s self-identity or self-reporting.  It should notbe based on physical appearance or surname.  **“Other” response option**  The NEDSS/HL-7 case notification message format allows reporting areas to select “other” as a response for this question. For the purposes of national TB surveillance, “other” is not an acceptable response and should not be used. |   **Example: Not Hispanic or Latino but has a Hispanic name**  A patient may have a Hispanic name but may not be Hispanic or Latino. For example, if a woman who is not Hispanic marries a Hispanic man, she may self-report as “Not Hispanic or Latino.” Similarly, people from the Philippines may have Hispanic names, but self-report as “Not Hispanic.” |

1. **Race**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To establish the patient’s race(s) for evaluation of epidemiologic trends associated with race. |  |  |  | | --- | --- | | **Option** *(****select one******or more)*** | **Description** | | **American Indian or Alaska Native** | Patient has origins in **any** of the original peoples of North and South America (including Central America). | | **Asian** | Patient has origins in **any** of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent (e.g., including Bangladesh, Cambodia, China, India, Indonesia, Japan, Korea, Malaysia, Nepal, Pakistan, the Philippine Islands, Thailand, and Vietnam). | | **Black or African American** | Patient has origins in **any** of the black racial groups of Africa. | | **Native Hawaiian or Other Pacific Islander (NHOPI)** | Patient has origins in **any** of the original peoples of Hawaii, Guam,  American Samoa, or other Pacific Islands, except islands considered to be part of Asia (see table on next page). | | **White** | Patient has origins in **any** of the original peoples of Europe, the Middle East, or North Africa. | | **Other Race** | Patient identifies to another race **not** listed above. | | **Unknown** | Patient’s Race is **not** reported or unknown. |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  | | --- | | **Note: Self-identity or self-reporting**  The response to this item should be based on the patient’s self-identity or self-reporting.  Therefore, patients should be offered the option of selecting more than one racial designation. Non-Hispanic patients who report more than one race will be reported as “multiple race” in national surveillance data summaries.  For Asian or Native Hawaiian or Other Pacific Islander, use the detailed race categories on the next page to complete Specify. The chart below indicates who is considered Asian and who is considered Native Hawaiian or other Pacific Islander. |   **National Electronic Disease Surveillance System (NEDSS)**  **Person Race Categories for Asian and for  Native Hawaiian or other Pacific Islander**     |  |  |  |  | | --- | --- | --- | --- | | **Asian** | | **Native Hawaiian or  other Pacific Islander** | | | Asian Indian  Bangladeshi  Bhutanese  Burmese  Cambodian  Chinese  Filipino  Hmong  Indonesian  Iwo Jiman  Japanese  Korean | Laotian  Madagascar  Malaysian  Maldivian  Nepalese  Okinawan  Pakistani  Singaporean  Sri Lankan  Taiwanese  Thai  Vietnamese | Carolinian  Chamorro  Chuukese  Fijian  Guamanian  Kiribati  Kosraean  Mariana Islander  Marshallese  Melanesian  Micronesian  Native Hawaiian | New Hebrides  Other Pacific Islander  Palauan  Papua New Guinean  Pohnpeian  Polynesian  Saipanese  Samoan  Solomon Islander  Tahitian  Tokelauan  Tongan  Yapese | | |

**11. Nativity**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To establish the patient’s country of birth and citizenship status at birth for evaluation of epidemiologic trends. |   **A. Country of Birth**   |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Specify** (e.g., United States, Mexico, China) | Enter the name of the country in which the person was born. If the person was born in a U.S. territory or a freely associated state, specify the name of the territory or state; do not enter “United States” unless the person was born in one of the 50 U.S. states or the District of Columbia. | Provide the actual country of birth for all patients regardless of whether they were U.S. citizens at birth. | | **Date of First U.S. Arrival** (**If NOT born in United States)** | Date (mm/dd/yyyy) patient first arrived in one of the 50 U.S. states or the District of Columbia, if the patient was born elsewhere. This date should be provided regardless of whether the patient was already a U.S. citizen at the time of first arrival in the United States. Partial dates are acceptable. | If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 04/99/1968) or 99/99/1968. |  |   **B. Eligible for U.S. Citizenship/Nationality at Birth (regardless of country of birth)?**   |  |  |  | | --- | --- | --- | | **Option**  ***(select one)*** | **Description** | **Comment** | | **Yes** | Eligible for U.S. citizenship *at birth*. | In certain circumstances, a person might be *eligible* for U.S. citizenship at birth, but the parents must take additional steps to *acquire* citizenship for their child. More information is available at:  <https://travel.state.gov/content/travel/en/legal/travel-legal-considerations/us-citizenship/Acquisition-US-Citizenship-Child-Born-Abroad.html> | | **No** | **Not** eligibleforU.S. citizenship *at birth*. | Answer “No” if the patient was not eligible for U.S. citizenship at birth, regardless of the patient’s current citizenship status. | | **Unknown** | Not known if patient was eligible for U.S. citizenship *at birth*. |  |   **C. Countries of Birth for Primary Guardian(s) (pediatric [<15 years old] patients only)**   |  |  | | --- | --- | |  | Country | | Guardian 1 |  | | Guardian 2 |  |  |  | | --- | | **Note: Country of birth.**  In order to distinguish persons who were born in another country (whether they had U.S. citizenship by birthright) from those who were born in the United States, this question simply asks to record the actual country of birth.  **Citizenship at birth.** This information is requested because the U.S. Census Bureau bases its “native-born” and “foreign-born” population estimates on this characteristic. As CDC uses the U.S. Census Bureau population estimates as denominator data in calculating incidence rates, this information is needed to correctly categorize TB patients as U.S.-born or non-U.S.–born. | |

1. **COUNTRY OF USUAL RESIDENCE**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To determine whether a patient was a resident of the United States at the time of diagnosis. |  |  |  | | --- | --- | |  | **Description** | | **Country of Usual Residence** | Country where patient usually resides. |   If NOT U.S. Reporting Area, Remained in United States for ≥90 days (inclusive of Report Date)?   |  |  |  | | --- | --- | --- | | **Option**  ***(select one)*** | **Description** | **Comment** | | **Yes** | Patient remained in the United States for ≥90 days inclusive of report date. |  | | **No** | Patient remained in the United States <90 days inclusive of report date. |  | | **Unknown** | It is **not** known how long the patient remained in the United States. |  |  |  | | --- | | **Note: Summary of updated guidelines for determining “country of usual residence”**  The Council of State and Territorial Epidemiologists (CSTE) recommends that cases of nationally notifiable diseases should be reported to CDC by the jurisdiction of the person’s “usual residence” at the time of disease onset. The following information has been adapted from [CSTE position statement 11-SI-04](https://wwwn.cdc.gov/nndss/document/11-SI-04.pdf) (“Revised Guidelines for Determining Residency for Disease Notification Purposes”). In addition, because notifiable disease data are often combined with population data, case notification guidelines based on census residence rules will contribute toward greater consistency in the numerator and denominator data used in disease rates.  **Usual residence is defined as the place where the person lives and sleeps most of the time**, which is not necessarily the same as the person's voting residence, legal residence, or the place where they became infected with a notifiable disease. Determining usual residence for most people is easy and unambiguous. However, the usual residence for some people is not obvious.  Persons, regardless of citizenship, who have established a household or are part of an established household (i.e., a “usual residence”) in the United States should be reported with a country of usual residence of “United States.” This includes persons who are in the United States for an extended period for work or study, even if they do not consider the United States to be “home.”  Persons (including U.S. citizens) whose established household is outside of the United States (e.g., they are “just visiting”) should be reported with a country of usual residence that is the country where they have established a household (including persons born in a U.S. territory or a freely associated state).  Persons with established households in more than one country should have country of usual residence determined based on which country they spent the most time in during the year preceding diagnosis. | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To determine if the patient was alive at the time of TB diagnosis. |  |  |  |  | | --- | --- | --- | | **Option**  *(****select one****)* | **Description** | **Comment** | | **Alive** | Patient was alive at time  laboratory results confirming a TB diagnosis (e.g., positive culture or nucleic acid amplification [NAA] test result consistent with TB) were known to the provider  **or**  TB medications were started | If the patient   * Was known to be culture or NAA test result positive consistent with TB before the date of death, but did not start TB therapy per ATS/CDC/IDSA guidelines, classify the patient as alive at TB diagnosis * Started empiric therapy for TB disease (per ATS/CDC/IDSA guidelines), but TB was not verified until after the patient’s death, classify as alive at TB diagnosis * Started TB therapy, regardless of laboratory or clinical confirmation for TB diagnosis, classify the patient as alive at TB diagnosis   *Note: Latent TB infection treatment does not count as TB treatment.* | | **Dead** | Patient was deceased at the time laboratory results confirming a TB diagnosis (e.g., positive culture or NAA test result consistent with TB) were known to the provider | * If diagnostic specimens were collected for evaluation of TB prior to death, but positive results to make a diagnosis of TB were not available until after death, and patient did not start TB therapy, classify as dead at TB diagnosis * If TB diagnosis was made after death based on a constellation of clinical and other findings (e.g., symptoms, TST, and imaging studies) in the absence of laboratory confirmation, and the patient did not start therapy, classify as dead at TB diagnosis * If patient was receiving treatment for latent TB infection at death because the patient was not believed to have TB disease, and TB was diagnosed after death, classify as dead at TB diagnosis * If patient was diagnosed at autopsy, classify as dead at TB diagnosis | |

1. **STATUS AT TB DIAGNOSIS**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To ascertain trends in how TB cases come to the attention of the medical or public health establishment. |  |  |  |  | | --- | --- | --- | | **Option**  *(****select one****)* | **Description** | **Comment** | | **Contact investigation** | A health department investigation to identify persons who had close contact with an infectious TB case. This also includes source case investigations to identify the source of TB transmission to a child with TB disease. | Select if TB diagnosis was made based on a contact investigation evaluation and testing results from this investigation. | | **Screening** | Any type of planned screening for TB in a specific population, other than among contacts of a TB case. | Screening includes “targeted testing” of high-risk populations (e.g., B notification, status adjusters), administrative screening required for employment, preenrollment screening of students, and similar activities, regardless of whether the screening activity was consistent with CDC recommendations. | | **TB symptoms** | Signs and symptoms consistent with TB (e.g., prolonged persistent cough, fever, lymphadenopathy, night sweats, weight loss). | TB symptoms should only be selected if the patient has TB symptoms at the time of diagnostic evaluation and neither Contact Investigation nor Screening apply to the case. This response is most appropriate when the reason that the patient came to the attention of the medical community was because of the patient’s TB symptoms. | | **Other** | Reason that does not fit into any of the above categories | Other reasons such as incidental lab results or findings | | **Unknown** | Reason for evaluating the patient **not** known |  |  |  | | --- | | **Note:** Select the **single initial reason** the patient was evaluated for TB disease. The definition of “initial reason” is the situation or reason that led to the initial evaluation for TB disease. If the patient was referred for evaluation, but the reason for the evaluation is unknown, try to determine that reason. | |

**14. INITIAL Reason Evaluated for TB**

**Example: TB Symptoms**

If a TB patient was initially encountered via a contact investigation and during that investigation was also noted to have TB symptoms, select **Contact Investigation** as the initial reason for the evaluation. However, if a patient seeks medical care because of TB symptoms, select **TB Symptoms** as the initial   
reason for the evaluation.

**RISK FACtors**

**15. CURRENT OCCUPATION AND INDUSTRY**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To evaluate potential associations between workplace exposures and TB by collecting information about the person’s current occupations and industries. |   A. Has the patient **ever** worked as one of the following? (select all that apply)   |  |  | | --- | --- | | **Option**  *(select all that apply)* | **Description** | | **Health care worker** | Paid or unpaid person working in a health care setting, with potential for  exposure to *M. tuberculosis*. Also known as “healthcare personnel.” | | **Correctional facility employee** | Person working in a correctional facility. Persons who have worked as health care personnel within a correctional facility should have both the “Health care worker” box and the “Correctional facility employee” box checked. | | **Migrant/seasonal worker** | Person who is required to be absent from a permanent place of residence for the purpose of seeking employment, or who may vary their employment for the purpose of remaining employed while maintaining a permanent place of residence. | | **None of the above** | Select if confirmed that the individual never worked as a health care worker, correctional facility employee, or migrant/seasonal worker. | | **Unknown** | Select only when it cannot be confirmed or denied that the individual ever worked as a health care worker, correctional facility employee, or migrant/seasonal worker. |   B. Current Occupation and Industry (complete this section for all patients ≥14 years of age [NIOSH standard], regardless of answers to part A)   |  |  |  |  | | --- | --- | --- | --- | | **Option** | **Description** | | **Comment** | | Narrative Description (Required) | Current Occupation is the type of job that the patient has been doing most recently, whether paid or unpaid (volunteer).  **Use this question:**  **“What kind of work do you do? For example, registered nurse, janitor, cashier, auto mechanic, barber, civil engineer, volunteer firefighter, etc.”** | | * If the patient has more than one current job, collect information on all of the patient’s jobs for entry in the repeating group. * If the patient is unemployed and is not currently seeking employment (e.g., patient is retired, disabled, or a full-time student), do not leave the Current Industry and Current Occupation fields blank; instead write “unemployed,” “disabled,” or “student.” Include the level of study for students, e.g., “college student” or “high school student.” * If the works on a voluntary basis, record what they do in the occupation field (e.g., zoo volunteer, school volunteer, library volunteer).   **Tips for getting the best information on occupation that can be coded:**   * **Be descriptive:**   Clearly describe the kind of work.   * Unhelpful: “teacher” * Helpful: “preschool teacher,” “high school teacher” * **Be specific:**   General or vague terms do not always provide enough information to code.   * Unhelpful: “laborer” * Helpful: “bricklayer” * Unhelpful: “worked in a warehouse,” “worked in a shipping department” * Helpful: “forklift operator” | | **Option** | | **Description** | **Comment** | | **Narrative Description (Required)** | | Current Industry is the kind of business or industry the patient works in. For each of the patient’s current occupations, the corresponding current industry should be reported.  This is NOT the name of the employer, although if the correct industry is not apparent, it is acceptable to enter the name, city, and state of the specific employer.  **Use this question:**  **“What kind of business or industry do you work in? For example, a hospital, dairy farm, restaurant, trade school, library, etc.”** | **Tips for getting the best information on industry that can be coded:**   * If industry is not obvious, ask what is the main focus or product of the employer for which the person works.   For example, if a patient says they work in manufacturing, ask what was made at the manufacturing plant. For example:   * Unhelpful: “manufacturing” * Helpful: “automobile manufacturing” * **Be specific:**   General or vague terms do not always provide enough information to code:   * Unhelpful: “food industry” * Helpful: “restaurant” or “grocery store” | |

**16. OTHER Risk Factors**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To evaluate potential risk factors for TB disease. |  |  |  | | --- | --- | | **Option**  ***(select all that apply)*** | **Description** | | **Diabetic at Diagnostic Evaluation** | Patient was diabetic (see description below) when TB diagnostic evaluation was performed or initiated. | | **Homeless in the Past 12 Months** | Patient has been homeless within the 12 months preceding the TB diagnostic evaluation. | | **Homeless Ever** | Patient has ever experienced homelessness. | | **Resident of Correctional Facility at Diagnostic Evaluation** | Patient was incarcerated or detained in a jail, prison, or other detention center when TB diagnostic evaluation was performed or initiated. | | **Resident of Correctional Facility Ever** | Patient has ever been incarcerated or detained in a jail, prison, or other detention center at any point in their lifetime. | | **Resident of Long-Term Care Facility at Diagnostic Evaluation** | Patient was a resident of long-term care facility when TB diagnostic evaluation was performed or initiated. | | **Injecting Drug Use in the Past 12 Months** | Patient used injection drugs in the past 12 months not prescribed by a healthcare provider. | | **Noninjecting Drug Use in the Past 12 Months** | Patient used noninjection drugs in the past 12 months not prescribed by a healthcare provider or approved by FDA for over-the-counter dispensing. | | **Heavy Alcohol Use in the Past 12 Months** | Patient heavily used alcohol (see definition below) in the past 12 months. | | **TNF-α antagonist therapy** | Patient recently received, or was receiving, tumor necrosis factor-alpha (TNF-α) antagonist therapy when TB diagnostic evaluation was performed or initiated. | | **Post-organ transplantation** | Patient has ever received a solid organ transplant (e.g., kidney, heart). | | **End-stage renal disease** | Patient had end-stage renal disease when TB diagnostic evaluation was performed or initiated (e.g., patients on dialysis). | | **Viral Hepatitis (B or C only)** | Patient has ever had a diagnosis of Hepatitis B or C (acute or chronic). | | **Other Immunocompromise (other than HIV/AIDS)** | Patient is immunocompromised because of either a medical condition (e.g., leukemia, Hodgkin’s lymphoma, carcinoma of the head or neck), or immunosuppressive therapy, such as prolonged use of high-doses of corticosteroids. | | **Other (specify)** | Additional risk factors as defined by the reporting area may be entered as “Other.” The particular risk factor being reports should be identified in the “specify” field. An unlimited number of “other” risk factors may be reported. |  |  |  | | --- | --- | | **Option**  *(****select one****)* | **Description** | | **No** | Patient does **not** have this risk factor. | | **Yes** | Patient has this risk factor. | | **Unknown** | It is unknown whether the patient has this risk factor |  |  |  |  | | --- | --- | --- | | **Note:**  **Definition for Diabetic**  The American Diabetes Association (American Diabetes Association. *Dia Care*. 2014;37:S81-S90) has established the following criteria for a diagnosis of diabetes:   * Hemoglobin A1c ≥6.5%, *or* * Fasting (defined as no caloric intake for ≥8 hours) plasma glucose ≥126 mg/dL (7.0 mmol/L), *or* * 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test, as described by the World Health Organization, *or* * In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L)   Persons who do not meet the above criteria only because they are currently receiving treatment for diabetes should still be reported as diabetic.  **Definitions for Homeless**  A **homeless** person may be an individual who has:   1. No fixed, regular, and adequate nighttime residence, and 2. A primary nighttime residence that is    1. A supervised publicly or privately operated shelter designed to provide temporary living  accommodations, including welfare hotels, congregate shelters, and transitional housing for the mentally ill, **or**    2. An institution that provides a temporary residence for individuals intended to be  institutionalized, **or**    3. A public or private place not designated for, or ordinarily used as, a regular sleeping  accommodation for human beings.   A **homeless** person may also be defined as a person who has no home (e.g., is not paying rent, does not own a home, and is not steadily living with relatives or friends). Persons in unstable housing situations (e.g., alternating between multiple residences for short stays of uncertain duration) may also be considered homeless.  A **homeless** person may be a person who lacks customary and regular access to a conventional dwelling or residence. Included as homeless are persons who live on streets or in nonresidential buildings. Also included are residents of homeless shelters and shelters for battered women. Residents of welfare hotels and single room occupancy (SRO) hotels could also be considered homeless. In the rural setting, where there are usually few shelters, a homeless person may live in nonresidential structures, or substandard housing, or with relatives. *Homeless* does not refer to a person who is imprisoned or in a correctional facility.  **Definition of Injecting Drug Use** Injecting drug use involves the use of hypodermic needles and syringes for the injection of drugs not prescribed by a health care provider. Route of administration may be intravenous, subcutaneous (e.g., skin popping), or intramuscular.  *Commonly injected drugs*   |  |  | | --- | --- | | * Heroin and other opiates (e.g., Demerol, Dilaudid, morphine, fentanyl) * Cocaine (e.g., speedball) * Methamphetamines * Amphetamines | * Phencyclidine (PCP, angel dust) * Other hallucinogens * Barbiturates * Steroids * Other hormones * Other stimulants |   **Definition of Noninjecting Drug Use**  Noninjecting drug use involves the use of licensed or prescription drugs or other drugs that were not injected and were not prescribed for the patient by a health care provider or approved for over-the-counter use by FDA, or misuse of prescribed drugs. The drugs may be ingested, inhaled, sniffed, or smoked. Marijuana use should always be recorded as noninjecting drug use, regardless of whether marijuana is legal for medicinal or recreational use in the state of residence.    **Heavy Alcohol Use in the Past 12 Months**  Heavy alcohol use is defined as binge drinking on 5 or more days in the month preceding diagnosis. Binge drinking is defined as a pattern of drinking that bring blood alcohol concentration levels to 0.08 g/dL. This typically occurs after four drinks for women and five drinks for men in about 2 hours. | |

**17. IF Resident of Correctional Facility at Diagnostic Evaluation, Type of Facility?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To categorize the type of correctional facility for those patients who were residing in a correctional facility at the time of diagnostic evaluation. |  |  |  | | --- | --- | | **Option**  *(****select one****)* | **Description** | | **Federal prison** | Confinement facility administered by a federal agency (except Immigration and Customs Enforcement); includes privately operated federal correctional facilities. | | **State prison** | Confinement facility administered by a state agency; includes privately  operated state correctional facilities. | | **Local jail** | Confinement facility usually administered by a local law enforcement agency, intended for adults but sometimes also containing juveniles; holds persons detained pending adjudication and/or persons committed after adjudication, typically for sentences of 1 year or less. | | **Juvenile correctional facility** | Public or private residential facility; includes juvenile detention centers, reception and diagnostic centers, ranches, camps, farms, boot camps, residential treatment centers, and halfway houses or group homes designated specifically for juveniles. | | **Other** | Includes Immigration and Customs Enforcement (ICE) detention centers, Indian reservation facilities (e.g., tribal jails), military stockades and jails, federal park police facilities, police lockups (temporary holding facilities for persons who have **not** been formally charged in court), or other correctional facilities that are **not** included in the other specific choices. | | **Unknown** | Inmate when the TB diagnostic evaluation was performed, but the type of correctional facility is **not** known. |  |  | | --- | | **Note:** If the TB patient was a resident of more than one facility during the diagnostic evaluation, select the facility where the initial TB diagnostic evaluation was performed. This question should only be completed if “Resident of Correctional Facility at Diagnostic Evaluation” is answered as “Yes” in question 16. | |

**18. IF Resident of long-term care facility at diagnostic evaluation, Type of Facility?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To categorize the type of long-term care facility for those patients who were residing in a long-term care facility at the time of diagnostic evaluation. |  | **Option**  *(****select one****)* | **Description** | **Comment** | | --- | --- | --- | | **Nursing home** | Freestanding facility with three or more beds (i.e., is classified as a residential facility or congregate residential setting) that provides nursing care services (e.g., nursing or medical care or supervision of medications that may be self-administered). | Facilities may be certified by Medicare or Medicaid or may be licensed by the state as a nursing home (e.g., skilled nursing facility, intermediate care facility, nursing care unit of a retirement center). | | **Hospital-based facility** | Distinct unit with three or more beds that is physically attached to, or managed by, a hospital. | Facilities may be certified by Medicare or Medicaid or may be licensed by the state. | | **Mental health  residential facility** | Facility that provides 24-hour care in a hospital, residential treatment, or supportive setting. | Include state, local, and private psychiatric hospitals, general hospitals, Department of Veterans Affairs facilities, residential mental health treatment centers for children, and multiservice mental health residential treatment programs.  For other mental health residential facilities, select “Other” long-term care facility.Examples include the Department of Defense, Bureau of Prisons, Public Health Service, Indian Health Service, and Indian reservation facilities. | | **Alcohol or drug treatment facility** | Only long-term rehabilitation or residential facilities designated for treatment of **30 days or longer.** | Exclude all ambulatory or outpatient facilities, detoxification units, and facilities designated for fewer than 30 days of treatment. The state agency responsible for alcohol and drug treatment can assist in determining whether a facility is considered residential. | | **Residential facility** | Facility with three or more beds (i.e., classified as a residential facility or congregate residential setting) and meets both of the following criteria:  1) Not classified as a nursing home, hospital-based facility, mental health residential facility, or alcohol or drug treatment facility, as described above  **and**  2) Provides personal care or supervision (not nursing care services) to its residents, in addition to room and board (e.g., help with bathing, dressing, eating, walking, shopping). | This might be an assisted living facility. | | **Other** | A facility **not** mentioned above that is designated for treatment of **30 days or longer and facility type is not Unknown.** |  | | **Unknown** | Patient known to be a resident of a long-term care facility, but the type of facility is **not** known. |  |  |  | | --- | | **Note:** If the TB patient was a resident of more than one facility during the diagnostic evaluation, select the facility where the initial TB diagnostic evaluation was performed. This question should only be completed if “Resident of Long-Term Care Facility at Diagnostic Evaluation” is answered as “Yes” in question 16. | |

**19. Current Smoking Status at Diagnostic Evaluation**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** Surveillance and patient management. To assess factors that may complicate testing, treatment, and follow-up. |  |  |  | | --- | --- | | **Option**  ***(Select one)*** | **Description** | | **Current every day smoker** | Patient currently smokes every day. | | **Current some day smoker** | Patient smokes some days, but not every day. | | **Former smoker** | Patient has smoked at least 100 cigarettes/cigars in his/her lifetime and has quit. | | **Never smoker** | Patient has not smoked at least 100 cigarettes/cigars in his/her lifetime. | | **Smoker, current status unknown** | Patient was a smoker, but current status is unknown. | | **Unknown if ever smoked** | Patient’s tobacco smoking history is not known. |  |  | | --- | | **Note:** The definition of smoking includes consumption of tobacco (or nicotine) through combustible tobacco products (e.g., cigarettes) or electronic nicotine delivery systems (ENDS; e.g., vapes or e-cigarettes). It does not include chewing tobacco. *Smoking of substances other than tobacco (e.g., marijuana) should be recorded under noninjecting drug use.*  Source: U.S. Food and Drug Administration. (2018). Vaporizers, E-Cigarettes, and other Electronic Nicotine Delivery Systems (ENDS). Retrieved from:  <https://www.fda.gov/TobaccoProducts/Labeling/ProductsIngredientsComponents/ucm456610.htm> | |

**20. LIVED OUTSIDE OF thE United states for >2 MONTHS (UNINTERRUPTED)?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To determine the extent to which persons with TB have traveled to countries that might pose a higher risk of TB exposure. |  |  |  |  | | --- | --- | --- | | **Option**  ***(select one)*** | **Description** | **Comment** | | **Yes** | Patient indicates that she/he has resided or traveled outside the United States (1 of the 50 states or the District of Columbia) for >2 months (uninterrupted). |  | | **No** | Patient did **not** live or travel outside the United States (1 of the 50 states or the District of Columbia) >2 months (uninterrupted). |  | | **Unknown** | No information is available about patient’s travel history. |  |  |  |  |  | | --- | --- | --- | | **Comment: Lived outside the United States**  Lived outside the United States refers to the place where a person stayed or slept most of the time, or the place the person considered home during the stated period.  **Example: Yes, lived outside the United States in as many as 3 countries for a total of more than 2 uninterrupted months**  From January 1 to March 15, the patient lived outside the United States   * Lived in Zambia for 10 weeks, then * Returned to the United States   **Example: Yes, lived outside the United States in as many as 3 countries for a total of more than 2 uninterrupted months**  From January 1 to March 15 the patient lived outside the United States   * Lived in Zambia for 4 weeks, then * Lived in South Africa for 3 weeks, then * Lived in Botswana 3 weeks, then * Returned to the United States   **Example: No, lived outside the United States in as many as 3 countries for a total of more than 2 months, but travel was interrupted**  From January 1 – March 15 the patient lived outside the United States   * Lived in Zambia for 5 weeks, then * Returned to the United States for 2 weeks, then * Lived in South Africa for 5 weeks, then * Returned to the United States | | | |  |  |  | |

**Diagnostic Testing  
(Other than Drug Susceptibility Testing [DST])**

1. **Tuberculin Skin Test and ALL Non-DST TB Lab Test Results**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To verify that the case meets the surveillance definition for TB and to identify laboratory test characteristics of TB cases. |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Date  collected/ Placed** | Month, day, and year the specimen was collected or tuberculin skin test (TST) was placed (e.g., 01/17/2020). |  | | **Date Reported/ Read** | Month, day, and year (mm/dd/yyyy) the laboratory reported the result, or the date that the TST was read. | This date can be found on the laboratory report as the date the report is released or made available.  In many instances, the result date and report date are the same; if not, provide the earliest date available. | | **Specimen Source Site** | Select appropriate anatomic source site from Appendix I. | For TST, the source site is always “skin.” |  |  |  |  | | --- | --- | --- | | **Test Type**  *(****select one****)* | **Description** | **Comment** | | **Smear** | Microscopic examination of specimen, e.g., sputum, using smear technique |  | | **Pathology/ Cytology** | Microscopic examination of specimen using histopathological or cytological methods |  | | **NAA** | Nucleic acid amplification testing (only when the specimen is tested directly; do not include results from tests on isolates obtained via culture) |  | | **Culture** | Mycobacterial culture of specimen to determine presence of *M. tuberculosis* complex (not nontuberculous mycobacteria) | For sputum specimens, select “sputum” from the value set, not “trachea,” “lung structure,” etc. | | **TST** | Tuberculin skin test | Routinely reporting TST/IGRA conversions is highly recommended. In the context of an outbreak, previous negatives or TST/IGRA conversions should be captured in the RVCT for outbreak-related cases.  If a person has a documented previous negative test and now tests positive, record both the previous negative and current positive result. | | **IGRA- QFT, IGRA-TSpot, IGRA- Unknown** | Interferon-gamma release assay (IGRA)  IGRA-QFT: QuantiFERON (any version)  IGRA-TSpot: T-Spot  IGRA-Unknown: If the specific type of IGRA test is unknown | | **HIV** | Serologic test for human immunodeficiency virus infection | Patient self-report of HIV status is not acceptable. HIV serology results must be documented. A documented positive test can be from any date; a negative test must be documented ≤12 months before the TB diagnostic evaluation. | | **CD4 Count** | Result of test for CD4 T-lymphocytes | Typically done with HIV patients to characterize the patient’s immune status. At least one CD4 count should be reported for HIV-positive patients, as close to the time of TB diagnostic evaluation as possible. Subsequent CD4 counts may also be reported. | | **Hemoglobin A1c** | Result of test to determine the average blood glucose level for the preceding several months | Typically done with diabetic patients or persons being screened for diabetes. At least one hemoglobin A1c or fasting blood glucose result should be reported for diabetic patients, as close to the time of TB diagnostic evaluation as possible. Subsequent hemoglobin A1c results may also be reported. | | **Fasting Blood Glucose** | Result of test to determine the blood glucose at a given moment in a patient who has not eaten in several hours | Typically done with diabetic patients or persons being screened for diabetes. At least one hemoglobin A1c or fasting blood glucose result should be reported for diabetic patients, as close to the time of TB diagnostic evaluation as possible. Subsequent fasting blood glucose results may also be reported. | | **Other**  **(Specify)** | Any other diagnostic tests that the reporting area wishes to include |  |  |  |  | | --- | --- | | **Test Result Qualitative**  *(****select one****)* | **Description** | | **Positive** | For tests with a qualitative (or interpreted) result, the test result was considered positive. | | **Negative** | For tests with a qualitative (or interpreted) result, the test result was considered negative. | | **Indeterminate** | For tests with a qualitative (or interpreted) result, the test result was considered indeterminate (neither positive nor negative). | | **Not Done** | Used to indicate that initial TST, initial IGRA, initial sputum smear, initial sputum culture, initial NAAT, or initial HIV test was not done in this case. | | **Unknown** | Used to indicate that the test was done but the result is unknown *or* that it is unknown if the test was done. |  |  |  | | --- | --- | | **Test Result Quantitative**  *(****select one****)* | **Description** | | **Quantitative result** | For tests with a quantitative (numerical) result, record the result in this field. These tests include the TST, CD4 cell count, hemoglobin A1c, fasting blood glucose. Quantitative result is not required for IGRA tests. | | **Quantitative units** | For tests with a quantitative (numerical) result, record the units of measurement, e.g., millimeters for TST, percentage for hemoglobin A1c. |  |  | | --- | | **Note:** Results of the tuberculin skin test (TST) should be interpreted according to Table 7 of the currently accepted guidelines ([www.cdc.gov/mmwr/PDF/rr/rr4906.pdf](http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf)) [see next page].  **MINIMUM REQUIREMENTS**:  Always enter initial TST, initial IGRA, initial sputum smear, initial sputum culture, initial NAAT, and initial HIV test. Enter "Not Done" if for any tests that were not done in this case.  CD4 count should be reported for HIV-positive persons. Hemoglobin A1c or fasting blood glucose at diagnostic evaluation should be reported for diabetic patients. Also include the initial result of any other tests performed that are in the test type value set. If a type of test was done on different specimen sources, include the initial result for each unique combination of test type and specimen source.  Follow-up testing should be done according to CDC guidelines and local clinical judgment. For tests that are done multiple times, only those results for each combination of test type and specimen source where the result changed (e.g., positive to negative) should be entered. |   **Guidelines for Entering TST Results**   |  |  | | --- | --- | | **Enter** | **Do Not Enter** | | Results from a TST performed during the current diagnostic evaluation. If the patient has a documented prior positive result, that result should be entered, and it is not necessary to repeat the test. | A patient’s undocumented self-report of a previous positive result is **not** acceptable |  **Interpreting the TST Reaction**  |  |  |  | | --- | --- | --- | |  |  |  | | **5 or more millimeters** | **10 or more millimeters** | **15 or more millimeters** | | An induration of ≥**5** millimeters is considered positive for   * People living with HIV * Recent contacts of persons with infectious TB * People who have previously had TB disease * Patients with organ transplants and other immunosuppressed patients (including patients taking a prolonged course of oral or intravenous corticosteroids or TNF-α antagonists) | An induration of ≥10 millimeters is considered positivefor   * People who have come to the U.S. within the last 5 years from areas of the world where TB is common (for example, Asia, Africa, Eastern Europe, Russia, or Latin America) * People who inject drugs * Mycobacteriology lab workers * People who live or work in high-risk congregate settings * People with certain medical conditions that place them at high risk for TB (silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, and certain intestinal conditions) * Children younger than 4 years * Infants, children, and adolescents exposed to adults in high-risk categories | An induration of ≥**15** millimeters is considered positive for   * People with no known risk factors for TB | |

**22. Chest Radiograph or Other Chest imaging study Results**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:**  To verify that the case meets the surveillance definition for TB and to identify imaging test characteristics of TB cases. |  |  |  | | --- | --- | | **Study Type** | **Description** | | **Plain Chest  X-ray** | Standard radiological study resulting in a 2-dimensional projection of internal thoracic structures onto film or a screen. | | **CT Scan** | Computed tomography, an advanced imaging technique using  X-rays to display 3-dimensional images of thoracic structures with computer assistance. | | **MRI** | Magnetic resonance imaging, an advanced imaging technique using strong magnetic fields to display 3-dimensional images of thoracic structures with computer assistance. | | **PET** | Positron emission tomography, an advanced imaging technique that uses radioactive tracers to identify areas of higher chemical activity in the body. | | **Other** | Select this option for imaging studies that do not fit into any of the above categories. |  |  |  | | --- | --- | | **Result Options**  *(****select one****)* | **Description** | | **Consistent with TB** | Any initial results showing abnormalities (e.g., hilar adenopathy, effusion, infiltrate[s], cavity, scarring) consistent with TB. | | **Not Consistent with TB** | Results showed **no** abnormalities consistent with TB. *This category includes any other abnormalities that are* ***not*** *consistent with TB.* | | **Not Done** | Used to indicate that a chest X-ray or chest CT scan was not done in this case. | | **Unknown** | Result of chest imaging is not known |  |  |  | | --- | --- | | **Cavity**  *(****select one****)* | **Description** | | **Yes** | The chest imaging studyshowed evidence of one or more cavities. | | **No** | Resultsdid **not** show evidence of one or more cavities. | | **Unknown** | It is **not** known if resultsshowed evidence of one or more cavities. |  |  |  | | --- | --- | | **Miliary**  *(****select one****)* | **Description** | | **Yes** | Resultsshowed evidence of miliary disease (e.g., miliary TB, or miliary or bilateral micronodular pattern). | | **No** | Resultsdid **not** show evidence of miliary disease (e.g., miliary TB, or miliary or bilateral micronodular pattern). | | **Unknown** | It is **not** known if resultsshowed evidence of miliary disease (e.g., miliary TB, or miliary or bilateral micronodular pattern). |  |  | | --- | | **Note:** Miliary TB is a serious type of TB disease. It is a clinical or radiologic finding, rather than a site of disease. Miliary TB is the result of a TB infection eroding into the bloodstream and from there disseminating throughout the body to multiple organs. It appears on radiographs as a great number of small (1- to 2-mm), well-defined nodules that look like millet seeds scattered throughout the lungs, hence the name “miliary.”  **MINIMUM REQUIREMENTS:** Initial plain chest x-ray; initial chest CT scan. Enter "Not Done" if applicable. Also include the initial result of any other chest imaging studies performed that are in the test type value set (i.e., MRI, PET). Subsequent results for each chest imaging study type should be entered if the result changed. Note if cavity or miliary lesions are identified for each study.  **Note:** The minimum requirement is the initial plain chest x-ray or initial chest CT scan result; however, multiple results may be entered into the table. | |

## **Clinical History and Findings**

**23. HAS THE PATIENT BEEN PreviousLY DiagnosED WITH TB Disease or LTBI?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To determine whether the patient has a prior history of TB disease or LTBI. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  | | --- | --- | | **History of Previous Illness**  *(****select one****)* | **Description** | | **Yes** | The patient has a history of previous TB disease or LTBI diagnoses.  Note: Written documentation of the previous episode of TB disease or LTBI is ideal. When written documentation is not available, self-report of a previous episode is acceptable (e.g., medication taken, length of course of medication, results of sputum smear examination). | | **No** | The patient did **not** have previous TB disease or LTBI diagnoses. | | **Unknown** | It is **not** known if the patient had previous TB disease or LTBI diagnoses. |   **If Yes:**   |  |  | | --- | --- | |  | **Description** | | **Diagnosis Type** | TB disease or LTBI | | **Diagnosis Date** | Date of previous diagnosis (provide date to the level of specificity that is available; self-report is acceptable). If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 04/99/1968 or 99/99/1968). | | **Previous State Case Number** | Provide previous TB state case number or LTBI state case number, if available |  |  |  | | --- | --- | | **Completed Treatment**  *(****select one****)* | **Description** | | **Yes** | The patient completed treatment.  **Note:** Written documentation of the previous episode of TB disease or LTBI is preferred. If the patient had a previous episode of TB that was reported to U.S. surveillance, contact the state in which the case was counted to obtain information about previous diagnoses and case outcomes. Otherwise, self-report is acceptable. | | **No** | The patient did **not** complete treatment. | | **Unknown** | It is **not** known if the patient completed treatment. | | |

**24. Date of Illness Onset/Symptom Start Date**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To establish the approximate symptom start date to facilitate calculation of infectious period and time from illness onset to diagnosis. |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Month,** **day, and year** (e.g., 01/17/2020) | Date illness/symptoms started for this TB episode. | Supply as much of the date as is known.  If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 04/99/2020) or 99/99/2020. |  |  | | --- | | **Note:** Some symptoms of TB can be nonspecific. The symptom onset date should be recorded as the approximate time when the patient first noticed one or more of the following TB symptoms:   * Severe cough that lasted at least 3 weeks * Chest pain not explained by another condition * Coughing up blood or sputum * Night sweats * Persistent fever not explained by another condition * Unintentional weight loss not explained by another condition | |

**25. Site of TB Disease**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To document site of TB disease. |  |  |  |  | | --- | --- | --- | | **Option**  *(****select all that apply****)* | **Description** | **Comment** | | **Site of TB Disease** | Select all anatomic sites where TB disease was identified in the patient from the provided list (Appendix I). | Site of disease does not always require laboratory identification. |  |  | | --- | | **Note:** If there is evidence that more than one organ or disease site is involved, select all involved sites of disease. “Pulmonary” has been replaced with “Lung Structure” in the provided list.  *Miliary TB*  This form has no place to select miliary TB in Site of Disease (item 25). If the report of the initial chest radiograph or the initial chest CT scan indicates “miliary TB or a miliary or bilateral micronodular pattern,” record this finding under Initial Chest Radiograph (item 22) and enter “Lung Structure” as a Site of Disease (item 25). | |

## **Epidemiologic Investigation**

**26. Case Meets Binational Reporting Criteria?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To determine whether the case meets binational reporting criteria. |  |  |  | | --- | --- | | **Option**  ***(select one)*** | **Description** | | **Yes** | The case meets binational reporting criteria.  *A case is considered binational when it meets one or more of the following criteria:*   * Exposure to suspected product (e.g., unpasteurized milk or cheese) from Canada or Mexico * Has case contacts in or from Mexico or Canada * Potentially exposed by a resident of Mexico or Canada * Potentially exposed while in Mexico or Canada * Resident of Canada or Mexico * Other situations that may require binational notification or coordination of response | | **No** | The case does **not** meet binational reporting criteria. | | **Unknown** | It is **not** known if the case meets binational reporting criteria. |   **If Yes:**  Which criteria were met (Select all that apply)?   |  |  | | --- | --- | | **Options**  ***(select all that apply)*** | **Description** | | Exposure to Suspected Product from Canada or Mexico | Patient exposed to a product (e.g., dairy product for *M. bovis* case) | | Has Case Contacts in or from Mexico or Canada | Patient has close contacts who live in Mexico or Canada | | Potentially Exposed by a Resident of Mexico or Canada | Patient was potentially exposed to a TB patient from Mexico or Canada | | Potentially Exposed while in Mexico or Canada | Patient was potentially exposed to TB while physically in Mexico or Canada | | Resident of Canada or Mexico | The patient is a resident of either Mexico or Canada | | Other Situations that May Require Binational Notification or Coordination of Response | Select this option if the case meets one of the following descriptions:   * The patient crossed the border into the United States from Mexico during TB treatment, or * The patient was referred to a U.S.-funded, binational TB program for treatment continuity (i.e, a patient who was being treated in the United States but it was known that he or she would cross the border to Mexico. |  |  | | --- | | **Note:** Information on Council of State and Territorial Epidemiologists (CSTE) binational case criteria is available in CSTE position statement 13-SI-02 ([www.cste.org/resource/resmgr/PS/13-SI-02.pdf](http://www.cste.org/resource/resmgr/PS/13-SI-02.pdf))  Information on the TB-specific binational case definition used to define “other situations that might require binational notification or coordination or response” is available in:  Woodruff RSY, Miner MC, Miramontes R. Development of a Surveillance Definition for United States–Mexico Binational Cases of Tuberculosis. *Public Health Reports* 2018;133(2):155–162.  <https://journals.sagepub.com/doi/pdf/10.1177/0033354918760575> | |

**27. Case Identified During A Contact Investigation OF Another Case?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To determine whether the case was identified during the contact investigation of another TB case. |  |  |  | | --- | --- | | **Option**  ***(select one)*** | **Description** | | **Yes** | Case was identified during the contact investigation of another case. | | **No** | Case was **not** identified during the contact investigation of another case. | | **Unknown** | It is **not** known if the case was identified during the contact investigation of another case. |   **If Yes:**  Evaluated for TB During that Contact Investigation     |  |  | | --- | --- | | **Option**  *(****select one****)* | **Description** | | **Yes** | Patient was evaluated for TB during that contact investigation, regardless of whether the patient was diagnosed with TB as part of that evaluation. | | **No** | Patient was **not** evaluated for TB during that contact investigation. | | **Unknown** | It is not known if patient was evaluated for TB during that contact investigation. | |

**28. Contact Investigation Conducted FOR This Case?**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To determine if a contact investigation was performed around this case. |  |  |  | | --- | --- | | **Option**  ***(select one)*** | **Description** | | **Yes** | Contact investigation was conducted for this case. | | **No** | Contact investigation was **not** conducted for this case. | | **Unknown** | It is **not** known if contact investigation was conducted for this case. |  |  | | --- | | **Note:** Contact investigations are often conducted based on a location, e.g., workplace, household. This question should be answered “yes” if a contact investigation was conducted that adequately identified contacts related to this case, even if the investigation was prompted by identification of a different case. | |

**29. Complete Table Below for All Known TB and LTBI Cases Epidemiologically Linked to this Case**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To determine potential transmission links between cases. |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Year** | Year Reported is the year when the case was reported (e.g., 2020). | This year should correspond to the Report Date, which is not necessarily the same as the *MMWR* Year. | | **State** | State Code indicates the two-letter postal code of the state reporting this case, e.g., GA for Georgia (see Appendix C, Reporting Area Codes). | The term *state* is used to refer to the reporting area, though not all reporting jurisdictions are states (e.g., New York City). | | **Number** | Nine-character string unique within the reporting area. | This string can contain letters or numbers and is assigned by the reporting area.  Enter “YYYY-ST-999999999” to indicate that an epidemiologic investigation (contact, source case, cluster, outbreak, etc.) was conducted for this case and no other TB cases or LTBI cases were identified that had epidemiological links with this case.  Leave blank if an investigation was not conducted, i.e., if question 28 is answered as “No” or “Unknown.” |  |  | | --- | | **Note:** For this variable, an “epidemiologic link” is defined as either a definite or probable link:   * *Definite:* patients shared airspace at the same location at the same time during one case's infectious period * *Probable:* patients shared airspace at the same location during the same general time period, but investigator unable to document that they were there at the same time during one case's infectious period | |

## **Initial Treatment Information**

**30. Date Therapy Started**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To calculate program management indicators. |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Month,** **day, and year** (e.g., 01/17/2020) | Date the patient began multidrug therapy for confirmed or possible TB disease | This may be one of several dates, ideally, when the patient first ingested medication if documented in a medical record. |  |  | | --- | | **Note:** Date Therapy Started is the month, day, and year the patient began drug therapy for confirmed or possible TB disease. Patient history without medical documentation is not acceptable and should be entered as unknown. Enter a date according to the following chart:  **Hierarchy of Determining Date Therapy Started**  **(Base decision on documented evidence)** | |

**31. Initial Drug Regimen**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To calculate program management indicators. |   For each drug named indicate whether it was used:   |  |  |  | | --- | --- | --- | | **Option**  ***(select one)*** | **Description** | **Comment** | | **Yes** | Drug is known to be part of the initial regimen.  Yesindicates that the drug was **initially** prescribed for treatment of TB disease. | . | | **No** | Drug is known to **not** be part of the initial regimen. |  | | **Unknown** | It is not known if drug is part of the initial regimen. |  | | **Note:** Combination drugs  For combination drugs, select Yes for each drug that is a component of the combination drug, e.g., for Rifater (combination of isoniazid, rifampin, and pyrazinamide):  **Initial Drug Regimen**   |  |  | | --- | --- | | Drug Name | Used?  (Yes/No/Unknown) | | Isoniazid | Yes | | Rifampin | Yes | | Pyrazinamide | Yes | | | | | |

**32. if Initial Drug Regimen NOT ripe/hrze (see note), WHY not?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To calculate program management indicators. |      |  |  | | --- | --- | | **Option**  *(****select one****)* | **Description** | | **Drug contraindication/interaction** | There was a pharmacologic contraindication or interaction that prevented the use of RIPE/HRZE (combination therapy with isoniazid, rifampin, pyrazinamide, and ethambutol) in this patient. | | **Drug susceptibility testing results already known** | The patient’s drug susceptibility results were already known, so a treatment regimen based on susceptibility results was used immediately. | | **Suspected drug resistance** | Drug susceptibility testing results were not yet available, but the provider suspected drug resistance, (e.g., the patient was a contact of a drug-resistant TB case), so a different regimen was used. | | **Drug shortage** | One or more RIPE/HRZE drugs could not be used because of national or local shortage of the drug(s). | | **Other (Specify)** | Other reason not covered in one of the provided categories. | | **Unknown** | There is insufficient documentation to determine why a regimen other than standard first-line therapy was used. |  |  | | --- | | **Note:** This question should only be completed if the standard initial four-drug therapy (RIPE/HRZE, i.e., isoniazid, rifampin, pyrazinamide, and ethambutol) was not used for this patient as recorded in question 31. | |

## **Genotyping and Drug Susceptibility Testing**

**33. Isolate Submitted for Genotyping?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To link genotyping results with RVCT data. |  |  |  |  | | --- | --- | --- | | **Option**  *(****select one****)* | **Description** | **Comment** | | **Yes** | Isolate was submitted for genotyping, regardless of genotyping results. |  | | **No** | **No** isolate was submitted for  genotyping. |  |   If **Yes**, enter the following information.   |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Genotyping accession number** | The genotyping accession number for the current TB episode. This number is assigned by the genotyping reference laboratory. | If multiple isolates have been submitted for one patient, please consult with your laboratorian or genotyping surveillance coordinator to determine the correct genotyping accession number for the current episode.  When entering the genotyping accession number, begin at the first box and continue to fill to the right. Include all hyphens and letters. Do not add zeros in the remaining boxes beyond the number provided by the reference lab. |  |  | | --- | | **Note:** **Genotyping accession number**  In 2004, CDC established the National Tuberculosis Genotyping Service (NTGS). The goal was to genotype one *M. tuberculosis* isolate from every culture-confirmed TB case in the United States. The genotyping accession number is the number assigned by the genotyping reference laboratory. Currently, the numbers are formatted as YY (the 2-digit year), followed by “RF” and 4 digits (e.g., “06RF5678”). This format might change in the future. | |

**34. WAS Phenotypic/Growth-Based Drug Susceptibility Testing Done?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To identify TB cases with drug-resistant isolates using phenotypic/growth-based drug susceptibility testing methods. |  |  |  | | --- | --- | | **Option**  *(****select one****)* | **Description** | | **Yes** | Growth-based drug susceptibility testing was performed. | | **No** | Growth-based drug susceptibility testing was **not** performed. | | **Unknown** | It is unknown whether growth-based susceptibility testing was performed |   **If YES, complete table for each drug tested**   |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Date  collected** | Month, day, and year the specimen was collected**.** (e.g., 01/17/2020) |  | | **Date Reported** | Month, day, and year (mm/dd/yyyy) the laboratory reported the result | This date can be found on the laboratory report as the date the report is released or made available.  In many instances, the result date and report dates are the same, if not, report the earliest date available. | | **Specimen Type** | Select appropriate anatomic source site from Appendix I. |  |   Foreach drug listed, select result option from the following.   |  |  | | --- | --- | | **Result Options** | **Description** | | **Resistant** | Any degree of resistance reported for drug. | | **Susceptible** | Select only if completely susceptible. | | **Unknown** | It is **not** known whether the test was performed.  **or**  Results were **not** available or result is not known for a reason other than pending results. |  |  | | --- | | **Note:** Include initial result for all unique combinations of drug tested and specimen type as well as any subsequent tests where the result changed when new test results become available. | |

**35. WAS GENOTYPIC/Molecular Drug Susceptibility Testing Done?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** Provides information on test results for genetic mutations associated with drug resistance. |  |  |  | | --- | --- | | **Option**  *(****select one****)* | **Description** | | **Yes** | Molecular drug susceptibility testing was performed. | | **No** | Molecular drug susceptibility testing was NOT performed. | | **Unknown** | It is not known if molecular drug susceptibility testing was performed. |   **If Yes, complete table for each gene tested (examples are in Appendix F):**   |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Gene Name** | Name of the gene associated with resistance to an anti-TB drug. |  | | **Date  collected** | Month, day, and year the specimen was collected (e.g., 01/17/2020). | Each test result should have a date collected. | | **Date Reported** | Month, day, and year (mm/dd/yyyy) the laboratory reported the result | This date can be found on the laboratory report as the date the report is released or made available. | | **Specimen Source Site** | Select appropriate anatomic source site from Appendix I. | For sputum specimens, select “sputum” from the value set, not “trachea,” “lung structure,” etc. |  |  |  |  | | --- | --- | --- | | **Results Options** | **Description** | **Comment** | | Mutation Detected | Mutation was detected. |  | | Mutation Not Detected | Mutation was not detected |  | | Unknown | It is not known if a mutation was detected. |  |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | Nucleic Acid Change | For each gene mutation, indicate the nucleic acid (NA) change associated with the mutation as indicated on the laboratory report. | Nucleic acid changes appear only if a mutation has occurred and a sequencing test type was performed. | | Amino Acid Change | For each gene mutation, indicate the amino acid (AA) change associated with the mutation as indicated on the laboratory report. | AA changes appear only if a mutation resulting in a substitution has occurred and a sequencing test type was performed. |  |  |  |  | | --- | --- | --- | | **Indel Options** | **Description** | **Comment** | | Insertion | Mark this option if an insertion is recorded or noted on the report. |  | | Deletion | Mark this option if a deletion is recorded or noted on the report. |  | | Indel | If a laboratory reports an insertion or a deletion but reports it as an “indel,” mark this option. |  | | Unknown | It is unknown whether an insertion, deletion, or “indel” is recorded or noted on the lab report. |  |  |  |  |  | | --- | --- | --- | | **Test Type Options** | **Description** | **Comment** | | Non-sequencing | Nonsequencing methods can be real-time PCR, line probe assay, or Xpert® MTB/RIF (Xpert® MTB/RIF applies only to the *rpoB* gene associated with rifampin resistance). | Nonsequencing methods do not usually have Nucleic Acid or Amino Acid changes reported on the laboratory report form. | | Sequencing | Pyrosequencing, Sanger sequencing, Next Generation Sequencing (NGS), Targeted-Based Sequencing, Targeted Sequencing, Amplicon-Based Sequencing, Whole Genome Sequencing (WGS). | Sequencing methods will usually have Nucleic Acid or Amino Acid changes recorded on the laboratory report form. | | Unknown | The testing method was unknown or not indicated on the laboratory report. |  |  |  | | --- | | **Note:** Include initial result for each combination of gene and test type as well as any subsequent tests where the result changed when new test results become available.  See Appendix E for additional instructions on completing this question, including examples. | |

**36. WAS THE PATIENT TREATED AS AN MDR TB CASE (REGARDLESS of dst results)?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To determine whether a patient was treated as a multidrug-resistant (MDR) TB case, regardless of laboratory results. |  |  |  |  | | --- | --- | --- | | **Option**  *(select one)* | **Description** | **Comment** | | **Yes** | The patient was treated as an MDR TB case. |  | | **No** | The patient was not treated as an MDR TB case. |  | | **Unknown** | It is not known whether the patient was treated as an MDR TB case. |  |  |  | | --- | | **Note:**  Sometimes, TB cases are treated as if they were MDR TB, even if laboratory results are not available to confirm the MDR TB diagnosis. These cases should have “Yes” entered for this question. If you selected **Yes**, complete the MDR TB supplemental form (Appendix G).  Do not mark this question as “Yes” if second-line TB drugs were used for reasons other than possible or confirmed drug resistance, e.g., drug sensitivity or shortage. | |

**Case Outcome**

**37. Sputum Culture Conversion Documented?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To monitor the rate of sputum culture conversion. |  |  |  |  | | --- | --- | --- | | **Option**  *(select one)* | **Description** | **Comment** | | **Yes** | Initial sputum specimen was culture-positive, followed by at least one negative sputum culture (not within initial set of sputa). | There should be no positive cultures after the negative culture(s) and no other positive cultures within the same “set” of sputa. | | **No** | Initial sputum specimen was culture-positive, and no subsequent sputum specimens were culture-negative. | Examples: all follow-up cultures were positive, patient could **not** produce sputum after therapy started, or no follow-up sputum cultures were obtained. | | **Unknown** | Results of all follow-up cultures are **not** known, or it is not known whether follow-up cultures were done. |  |   If you selected **Yes**, enter the following information.   |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Date specimen  collected for FIRST consistently negative sputum culture** | Month, day, and year when the first of the consistently negative sputum specimens was collected (e.g., 01/17/2020). | Complete only for patients who had one or more positive sputum cultures and who subsequently had at least one documented negative culture. A follow-up specimen can be collected at any time after treatment initiation.  There should be no positive cultures after this date. If a subsequent culture is positive after an initially documented sputum culture conversion, delete the originally documented date.  Provide as much of the date as is known.  If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 04/99/2020 or 99/99/2020). |   If you selected **No,** select the one best reason for not documenting sputum culture conversion:   |  |  | | --- | --- | | **Option**  *(select one)* | **Description** | | **No follow-up sputum despite induction** | Repeat sputum collection was attempted (including induced sputum collection), but because of clinical improvement, patient was **not** able to produce sputum. | | **No follow-up  sputum and no induction** | Repeat sputum collection was attempted, but induced sputum collection was not attempted and patient was **not** able to produce sputum. | | **Died** | Patient died before having an opportunity to submit sputum to document whether the sputum culture had converted. | | **Patient lost to follow-up** | Patient was lost to follow-up before having an opportunity to submit a sputum to document whether the sputum culture had converted. | | **Patient refused** | Patient refused to provide a sputum specimen for a repeat culture. | | **Other**  *(specify)* | A reason **not** included in the above choices (e.g., treatment failed or the patient moved outside the United States). | | **Unknown** | It is **not** known why a repeat sputum culture was **not** obtained. |  |  | | --- | | **Note:**  Provide information on sputum culture conversion only for patients with initially positive sputum cultures. Sources for documentation of sputum culture conversion include patient medical records and laboratory reports.  This question should be completed once sputum culture conversion is documented. If the patient’s sputum cultures later become positive again, the response to this question should be updated. | |

**38. Moved During Therapy?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To facilitate efficient communication between TB control programs in providing continuity of care for the patient. |  |  |  | | --- | --- | | **Option**  *(select one)* | **Description** | | **Yes** | Patient moved to an area where another reporting area must now provide or coordinate TB care. | | **No** | Patient did **not** move.  ***or***  Patient moved within the same reporting area. |   If you selected **Yes**, select all the options under “Moved to Where” that apply to the area to which the patient moved:   |  |  |  | | --- | --- | --- | | **Option**  *(select all that apply)* | **Description** | **Comment** | | **Out of state**  *(specify)* | Patient moved from one U.S. reporting area to another reporting area. For this question, “state” refers specifically to U.S. reporting areas. Moves from state to state *within* a U.S. reporting area (e.g., Federated States of Micronesia) should not be reported as an “out of state” move.  Enter the name of the state or reporting area to which the patient moved. | U.S. reporting areas include:   * The 50 U.S. states * District of Columbia * New York City (separately from New York State) * Puerto Rico * U.S. Virgin Islands * Guam * American Samoa * Commonwealth of the Northern Marianas Islands * Republic of the Marshall Islands * Federated States of Micronesia * Republic of Palau | | **Out of the U.S.**  *(specify)* | Patient moved from a U.S. reporting area to a country not considered a U.S. reporting area.  Enter the name of the country to which the patient moved. | For the purposes of this question, “U.S.” refers to all U.S. reporting areas, not just the 50 states and the District of Columbia. |   If patient moved **out of the U.S.**, select one option to indicate whether a **transnational referral** was made.   |  |  |  | | --- | --- | --- | | **Option**  *(select all*  *that apply)* | **Description** | **Comment** | | **Yes** | Patient was referred to a TB program or physician outside the United States. | Transnational referral includes participation in programs such as   * TBNet * CureTB   Communication between programs is important:   * to help ensure continued case management after a patient leaves the United States. * for completing a case management transfer and obtaining information from TB programs or physicians outside the United States for case completion. | | **No** | Patient was not referred to a TB program or physician outside the United States. |  |  | | --- | | **Note:** This variable is used to record whether the patient moved during TB therapy. The responsibility for follow-up reporting generally remains with the reporting area that initially reported the case to CDC and counted it. (For a detailed description of the responsibility for submitting follow-up reports to CDC, see the instructions for **Reporting Address** [item 6].) |   **Examples of Moved**   |  |  |  | | --- | --- | --- | | **Moved** | | **Select** | | **From** | **To** | | Dekalb County, Georgia | Fulton County, Georgia | Do not report as a move | | Yap, FSM | Chuuk, FSM | Do not report as a move | | Saipan, CNMI | Rota, CNMI | Do not report as a move | | California | Hawaii | Out of state | | Washington, D.C. | Baltimore, Maryland | Out of state | | California | Guam | Out of state | | New York City | New York State (outside of NYC) | Out of state | | Guam | Palau | Out of state | | Guam | Hawaii | Out of state | | Chuuk, FSM | Guam | Out of state | | Chuuk, FSM | California | Out of state | | Puerto Rico | Florida | Out of state | | Guam | China | Out of the U.S. | | California | China | Out of the U.S. | |

**39. Date Therapy Stopped**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To monitor completion of therapy within a specified time. |  |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Month,** **day, and year** (e.g., 01/17/2020) | Date the patient stopped taking medication for confirmed or possible TB disease | This may be one of several dates, ideally, when the patient last ingested medication if documented in a medical record. |  |  | | --- | | **Comment: Date Therapy Stopped**  The interval between Date Therapy Started (item 30) and Date Therapy Stopped (item 39) is meant to encompass the entire period (including interruptions in therapy) that the patient was receiving medication to treat confirmed or possible TB disease. Patient self-report without medical documentation is not acceptable. Although there may be interruptions in anti-TB drug therapy, enter the final documented date on which the patient last ingested medication for confirmed or possible TB disease. For patients being treated for confirmed or possible TB disease, enter Date Therapy Stopped, according to the following chart:  **Hierarchy for Determining Date Therapy Stopped**  **(for entire treatment period)** | |

**40. Reason Therapy Stopped or Never Started?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:**  To document treatment outcome. |  |  |  | | --- | --- | | **Option**  *(select one)* | **Description** | | **Completed therapy** | Patient completed the prescribed course of therapy per the medical record as recorded by the clinician caring for the patient. | | **Lost** | Patient could **not** be located before the start or the completion of treatment (e.g., the patient moved to an unknown location, or the forwarding address is known but the patient was **not** found at that address).  Code patients who move outside the United States and cannot be followed up as Other. | | **Uncooperative or refused** | Patient refused to start or complete therapy (e.g., stopped taking drugs). | | **Adverse treatment event** | Therapy was permanently stopped because of an adverse event due to anti-TB medications. *Select this option only if the patient survived the adverse event.*  If the patient died because of an adverse TB treatment event, select Died as the reason therapy stopped and note that the death was TB-related in item 43. | | **Not TB** | Completed diagnostic evaluation did **not** substantiate the diagnosis of TB (e.g., *M. avium* or *M. bovis* BCG was isolated from a clinical specimen). | | **Died** | Patient was alive at diagnosis but died before the start or completion of treatment. | | **Dying** | Treatment was stopped by the clinician or at patient request because the patient’s condition was terminal and death was imminent. | | **Other** | Therapy was discontinued for a known reason **not** included in the above choices and is **not** Unknown, (e.g., patient moved outside the United States, or patient moved from state A to state B, and state A notified state B, but state B never followed up). | | **Unknown** | Reason that therapy was stopped is **not** known. | |

**41. Reason TB Disease Therapy Extended >12 Months, if applicable**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:**  To document reason for extended treatment and to calculate program indicators. |  |  |  |  | | --- | --- | --- | | **Option**  ***(select all that apply)*** | **Description** | **Comment** | | **Inability to Use Rifampin (Resistance, Intolerance, etc.)** | Rifampin (or another rifamycin) could not be used to treat the patient (e.g., drug-resistant TB, rifampin intolerance), resulting in the treatment protocol lasting more than 12 months. |  | | **Adverse drug reaction** | Patient had a significant adverse drug  reaction or experienced an adverse treatment event from anti-TB medications that prolonged therapy. |  | | **Nonadherence** | There were barriers to the patient’s  adherence to anti-TB therapy (e.g., treatment interruption), resulting in extension of therapy beyond 12 months. |  | | **Failure** | A culture tested positive 4 or more months after treatment began, resulting in prolonged therapy. |  | | **Clinically indicated― other reasons** | Clinical indications (other than adverse drug reactions) include central nervous system TB (e.g., meningitis), severe liver disease, or other criteria as specified by the clinician. |  | | **Other (specify)** | Reason does **not** include any of the choices listed above. Specify the reason that therapy was extended. |  | | **Unknown** | Reason is unknown. |  |  |  | | --- | | **Note:** Use the information entered for Date Therapy Started (item 30) and Date Therapy Stopped(item 39) to calculate the length of anti-TB therapy. Sources for the reason(s) therapy was extended include patient medical records, patient interview, and health care provider interview. | |

**42. Treatment Administration**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To document administration of TB medications. |  |  |  | | --- | --- | | **Option**  ***(select all that apply)*** | **Description** | | **DOT** | Directly Observed Therapy (DOT), in person.Response applies if DOT was used for any doses for a patient. | | **EDOT** | Electronic DOT (EDOT), via video call or other electronic method.Response applies if EDOT (e.g., video call, electronic medication bottle) was used to document adherence to the medication regimen for any doses. | | **Self-Administered** | Any doses of medication were taken by the patient not under DOT or EDOT (including weekend doses). |  |  | | --- | | **Note:** Directly observed therapy (DOT), or supervised therapy, involves the direct visual observation by a health care provider (e.g., public health nurse, outreach worker, nurse, nurse’s aide) or other reliable trained person (e.g., worker in a homeless shelter) of a patient’s ingestion of medication. Delivering medication to a patient without visual confirmation of ingestion does not constitute DOT. However, electronic confirmation of ingestion of medicine of carefully selected patients (e.g., stable and compliant) constitutes electronic DOT. | |

**43. Did the Patient Die (either before diagnosis or at any time while being followed by TB program)?**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  | | --- | | **Primary Purpose:** To collect information on mortality among TB patients. |  |  |  | | --- | --- | | **Option**  ***(select one)*** | **Description** | | **Yes** | The patient died (for any reason) either before the TB diagnosis was made or at any point after TB diagnosis while the TB program was following the status of the patient. If this option is selected, record the date of death. | | **No** | The patient was alive at the time that the TB program stopped following up with the patient. | | **Unknown** | It is unknown whether the patient was alive or dead at the time that the TB program stopped following up with the patient. |   **If Yes:**   |  |  |  | | --- | --- | --- | |  | **Description** | **Comment** | | **Month,** **day, and year** (e.g., 010/20/2020) | Patient’s date of death should be entered (i.e., month, day, *and* year). | If the exact date of death is unknown, provide as much specificity as possible.  If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 10/99/2020) or 99/99/2020.  If the month, day, and year of death are unknown, enter 99/99/9999. |   Did TB or Complications of TB Treatment Contribute to Death?     |  |  |  | | --- | --- | --- | | **Option**  *(****select one****)* | **Description** | **Comment** | | **Yes** | TB or complications of TB treatment contributed to death. | Written documentation of the cause of death (e.g., death certificate, autopsy report, medical record) is recommended. However, oral information from a reliable source (e.g., a health care provider) will be accepted. A death certificate is not necessarily required to complete this field, and TB does not need to be listed as a cause of death on the death certificate to conclude that the death was TB-related for the purposes of the RVCT. | | **No** | TB or complications of TB treatment did **not** contribute to death. | TB was not the immediate cause, an underlying cause, or another significant condition contributing to death. | | **Unknown** | It is **not** known if TB or complications of TB treatment contributed to death. | Every effort should be made to determine if the death was related to TB disease before classifying as unknown. | |

# **Appendices**

The following appendices provide information and codes that are used to complete the RVCT:

* **Appendix A – Tuberculosis Case Definition for Public Health Surveillance**
* **Appendix B – Recommendations for Reporting and Counting Tuberculosis Cases**
* **Appendix C – Reporting Area Codes**
* **Appendix D – Anti-TB Drug Names and Genes Associated with Drug Resistance**
* **Appendix E – The RVCT Molecular drug susceptibility testing (DST) Report**
* **Appendix F – RVCT Molecular DST Report Examples**
* **Appendix G – MDR TB Supplemental Surveillance Form**
* **Appendix H – Instructions for MDR TB Supplemental Surveillance Form**
* **Appendix I – Anatomic Sites**
* **Appendix J – Glossary**

## **Appendix A**

Tuberculosis Case Definition for Public Health Surveillance

CSTE Position Statement 09-ID-65

**Clinical description**

A chronic bacterial infection caused by *Mycobacterium tuberculosis*, usually characterized pathologically by the formation of granulomas. The most common site of infection is the lung, but other organs may be involved.

**Clinical criteria**

A case that meets all the following criteria:

* A positive tuberculin skin test or positive interferon gamma release assay for *M. tuberculosis*
* Other signs and symptoms compatible with tuberculosis (TB) (e.g., abnormal chest radiograph, abnormal chest computerized tomography scan or other chest imaging study, or clinical evidence of current disease)
* Treatment with two or more anti-TB medications
* A completed diagnostic evaluation

**Laboratory criteria for diagnosis**

* Isolation of *M. tuberculosis* from a clinical specimen,\* *OR*
* Demonstration of *M. tuberculosis* complex from a clinical specimen by nucleic acid amplification test,\*\* *OR*
* Demonstration of acid-fast bacilli in a clinical specimen when a culture has not been or cannot be obtained or is falsely negative or contaminated.

**Case classification**

*Confirmed*

A case that meets the clinical case definition or is laboratory confirmed.

**Comments**

A case should not be counted twice within any consecutive 12-month period. However, a case occurring in a patient who had previously had verified TB disease should be reported and counted again if more than 12 months have elapsed since the patient completed therapy. A case should also be reported and counted again if the patient was lost to supervision for greater than 12 months and TB disease can be verified again. Mycobacterial diseases other than those caused by *M. tuberculosis* complex should not be counted in tuberculosis morbidity statistics unless there is concurrent tuberculosis.

\* Use of identification techniques for *M. tuberculosis* (e.g., DNA probes, real-time PCR, sequencing, or MALDI-TOF) performed on growth from culture of a clinical specimen are acceptable under this criterion.

\*\* Nucleic acid amplification (NAA) tests are rapid tests used for direct detection of *M. tuberculosis* from a clinical specimen. These tests must be accompanied by culture; a culture isolate of *M. tuberculosis* complex is required for complete drug susceptibility testing and also genotyping. However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug Administration (FDA) and used according to the approved product labeling on the package insert, or a test produced and validated in accordance with applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) regulations.

## **Appendix B**

**Recommendations for Reporting, Verifying, and Counting Tuberculosis Cases**

(**Revised November 21, 2019)**

Since publication of the 2009 Recommendations for Reporting and Counting Tuberculosis Cases, numerous changes have occurred, and many issues have been raised within the field of tuberculosis (TB) surveillance. This current version updates and supersedes the previous version. *Any changes in wording or format of this edition of these recommendations are intended only to clarify previous areas of confusion, not to substantively change any existing TB case counting recommendations, except where specifically indicated.*

In the National Tuberculosis Surveillance System (NTSS), a TB case goes through three distinct stages: possible (also known as “suspected”), verified, and counted.

**Possible Case**

A possible TB case exists when the local TB program is initially made aware of a patient with clinical signs, symptoms, or diagnostic test results that are consistent with TB. Ideally, reporting of possible cases occurs early in the diagnostic evaluation of the patient so that the local TB program can ensure appropriate case supervision, completion of appropriate therapy, and initiation of any necessary epidemiologic investigations.

**Verified Case**

Possible TB cases will either be verified or refuted with regard to meeting the TB surveillance case definition in Appendix A, “Tuberculosis Case Definition for Public Health Surveillance.” Refuted cases require no further action with regard to TB surveillance, and generally should not be reported to CDC. A verified TB case exists when the local TB program confirms that the patient’s laboratory results and clinical signs and symptoms meet the TB surveillance case definition. Verified cases are classified as either laboratory-confirmed or clinical cases as outlined below:

*Laboratory Case Definition*

Isolation of *Mycobacterium tuberculosis* complex[[1]](#footnote-2) from a clinical specimen. The use of identification techniques for *M. tuberculosis* performed on growth from culture of a clinical specimen, such as DNA probes, real-time PCR, sequencing, or MALDI-TOF, is acceptable under this criterion.

**OR**

Demonstration of *M. tuberculosis* complex\* from a clinical specimen by nucleic acid amplification (NAA) test. NAA tests must be accompanied by cultures of mycobacterial species. However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug Administration (FDA) and used according to the approved product labeling on the package insert, or a test produced and validated in accordance with applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) regulations.

**OR**

Demonstration of acid-fast bacilli (AFB) in a clinical specimen when a culture has not been or cannot be obtained or is falsely negative or contaminated; historically this criterion has been most commonly used to diagnose TB in the postmortem setting.

*Clinical Case Definition*

In the absence of laboratory confirmation of *M. tuberculosis* complex after a diagnostic process has been completed, persons must have **all** of the following criteria for clinical TB:

Evidence of TB infection based on a positive tuberculin skin test result or positive interferon-gamma release assay for *M. tuberculosis*

**AND**

Signs and symptoms compatible with current TB disease, such as a chest radiograph, chest computerized tomography scan, or other chest imaging study with results that are consistent with TB or clinical evidence of current disease (e.g., fever, night sweats, cough, weight loss, hemoptysis)

**AND**

Current treatment with two or more anti-TB medications

Reporting of all verified cases to CDC is required by the cooperative agreement between CDC and state and local TB programs, regardless of whether the case is counted as part of the jurisdiction’s official TB case count, as explained below.

NOTE: The software for TB surveillance developed by CDC includes a calculated variable called VERCRIT, for which one of the values is “Provider Diagnosis.” “Provider Diagnosis” is selected when the user chooses to override a “Suspected” (corresponding to a “possible” case as described in these recommendations) default value in the case verification screen as “Verified by Provider Diagnosis.” Thus, “Provider Diagnosis” is not a component of the case definition for TB in the current “Tuberculosis Case Definition for Public Health Surveillance” (Appendix A). CDC’s national morbidity reports have traditionally included all TB cases that are considered verified by the reporting areas, without a requirement that cases meet the published case definition.

**Counted Case**

A counted TB case exists when the NTSS reporting area (each of the 50 states, New York City, the District of Columbia, and the eight U.S.-affiliated island reporting areas) determines that a verified case has not already been counted in another NTSS reporting area or by another country that is not an NTSS reporting area. For situation-specific guidance on whether and when to count a verified TB case, see below:

Verified TB Cases

*Count*

Count only verified TB cases that meet the laboratory or clinical case definitions (see “Verified Case” above). The diagnosis of TB must be verified by the TB control officer or designee.

*Do not Count*

If diagnostic procedures have not been completed, do not count; wait for confirmation of disease. Do not count as a case the patient for which two or more anti-TB medications have been prescribed for preventive therapy for exposure to multidrug-resistant (MDR) TB, or while the diagnosis is pending.

Nontuberculous Mycobacterial Diseases

*Count*

An episode of TB disease diagnosed concurrently with another nontuberculous mycobacterial disease should be counted as a TB case.

*Do not Count*

Disease caused by nontuberculous mycobacteria alone should not be counted as a TB case.

TB Cases Reported at Death

*Count*

TB cases first reported to the health department at the time of a person’s death are counted as incident cases, provided the person had current disease at the time of death. The TB control officer should verify the diagnosis of TB.

*Do not Count*

Do not count as a case of TB if there is no evidence of current disease at the time of death or at autopsy.

Immigrants, Refugees, Permanent Resident Aliens, Border Crossers, and Foreign Visitors

*Count*

Immigrants and refugees who are examined after arriving in the United States and diagnosed with clinically active TB disease requiring anti-TB medications should be reported and counted by the locality of their current residence at the time of diagnosis regardless of citizenship status.

Border crossers who are diagnosed with TB and plan to receive anti-TB therapy from a locality in the United States for 90 days or more should be reported and counted by the locality where they receive anti-TB therapy. “Border crosser” is defined, by the U.S. Citizenship and Immigration Services (USCIS) as “an alien resident of the United States reentering the country after an absence of less than six months in Canada or Mexico, or a nonresident alien entering the United States across the Canadian border for stays of no more than six months, or across the Mexican border for stays of no more than 72 hours.”[[2]](#footnote-3)

Foreign visitors (e.g., students, commercial representatives, and diplomatic personnel) who are diagnosed with TB, are receiving anti-TB therapy, and have been, or plan to remain in, the United States for 90 days or more should be reported and counted by the locality of current residence.

*Do not Count*

Any person who was diagnosed and started on anti-TB drugs in another country should not be counted as a new case but should be reported as a verified noncountable TB case.

Border crossers and foreign visitors who are diagnosed with TB and receive anti-TB therapy from a locality in the United States for less than 90 days but plan to return to their native country to continue therapy should not be reported or counted by the locality where they receive anti-TB therapy.

Out-of-State or Out-of-Area Residents

*Count*

A person’s TB case should be counted by the locality in which he or she resides at the time of diagnosis. TB in a person who has no fixed address should be counted by the locality that diagnosed and is treating the person with TB. The TB control officer should notify the appropriate out-of-area TB control officer of the person’s home locality to (1) determine whether the case has already been counted to avoid “double counting,” and (2) agree on which TB control office should count the case.

*Do not Count*

Do not count a case in a newly diagnosed TB patient who is an out-of-area resident and whose TB has already been counted by the out-of-area TB control office.

Migrants and Other Persons without a fixed U.S. residence

*Count*

Persons without any fixed U.S. residence are considered to be the public health responsibility of their present locality and their TB case should be reported and counted where diagnosed.

*Do not Count*

Cases in transient TB patients should not be counted when there is evidence that they have already been counted by another locality.

Federal Facilities (e.g., Military and Veterans Administration Facilities)

*Count*

Cases in military personnel, dependents, or veterans should be reported and counted by the locality where the persons are residing in the United States at the time of diagnosis and initiation of treatment.

However, if military personnel or dependents are discovered to have TB at a military base outside the United States but are referred elsewhere for treatment (e.g., a military base located within the United States), the TB case should be reported and counted where treated and not where diagnosed.

*Do not Count*

Do not count if the case was already counted by another reporting area in the United States.

Tribal Lands

*Count*

TB should be reported to the local health authority (e.g., state or county) and counted where diagnosed and treatment initiated. However, for a group such as the Navajo Nation, which is geographically located in multiple states, health departments should discuss each case and determine which locality should count the case.

*Do not Count*

Do not count if the case was already counted by another locality.

Correctional Facilities (e.g., Local, State, Federal, and Military)

*Count*

Persons who reside in local, state, federal, or military correctional facilities may frequently be transferred or relocated within and/or between various correctional facilities. TB in these persons should be reported to the local health authority and counted by the locality where the diagnosis was made and treatment plans were initiated.

*Do not Count*

Do not count correctional facility residents’ TB cases that were counted elsewhere by another locality or correctional facility, even if treatment continues at another locale or correctional facility.

To promote uniformity in TB case reporting, the following administrative procedures are recommended:

* + All countable TB cases verified by the 50 U.S. states, New York City, and the District of Columbia by December 31and reported to CDC by the prescribed deadline will be included in the annual U.S. incidence count for that year.
  + All TB cases verified during the calendar year by one of the remaining 8 reporting areas (American Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands) are also counted but are not included in the annual incidence for the United States.
  + Cases for which bacteriologic results are pending or for which confirmation of disease is questionable for any other reason should not be counted until their status is clearly determined; they should be counted at the time they meet the case verification criteria. This means that a case reported in one calendar year could be included in the morbidity count for the following year.

## **Appendix C**

**Reporting Area Codes**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name** | **Alpha** | **Code** |  | **Name** | **Alpha** | **Code** |
| Alabama | AL | 01 |  | Nebraska | NE | 31 |
| Alaska | AK | 02 |  | Nevada | NV | 32 |
| Arizona | AZ | 04 |  | New Hampshire | NH | 33 |
| Arkansas | AR | 05 |  | New Jersey | NJ | 34 |
| California | CA | 06 |  | New Mexico | NM | 35 |
| Colorado | CO | 08 |  | New York | NY | 36 |
| Connecticut | CT | 09 |  | New York City | NO | 975772 |
| Delaware | DE | 10 |  | North Carolina | NC | 37 |
| Florida | FL | 12 |  | North Dakota | ND | 38 |
| Georgia | GA | 13 |  | Ohio | OH | 39 |
| Hawaii | HI | 15 |  | Oklahoma | OK | 40 |
| Idaho | ID | 16 |  | Oregon | OR | 41 |
| Illinois | IL | 17 |  | Pennsylvania | PA | 42 |
| Indiana | IN | 18 |  | Rhode Island | RI | 44 |
| Iowa | IA | 19 |  | South Carolina | SC | 45 |
| Kansas | KS | 20 |  | South Dakota | SD | 46 |
| Kentucky | KY | 21 |  | Tennessee | TN | 47 |
| Louisiana | LA | 22 |  | Texas | TX | 48 |
| Maine | ME | 23 |  | Utah | UT | 49 |
| Maryland | MD | 24 |  | Vermont | VT | 50 |
| Massachusetts | MA | 25 |  | Virginia | VA | 51 |
| Michigan | MI | 26 |  | Washington | WA | 53 |
| Minnesota | MN | 27 |  | Washington D.C. | DC | 11 |
| Mississippi | MS | 28 |  | West Virginia | WV | 54 |
| Missouri | MO | 29 |  | Wisconsin | WI | 55 |
| Montana | MT | 30 |  | Wyoming | WY | 56 |
| **U.S.-Affiliated Island Reporting Area Codes**  **For information on citizenship and “U.S.-born” for Island Areas see Nativity (item 11)** | | | | | | |
| **Name** | **Alpha** | **Code** |  | **Name** | **Alpha** | **Code** |
| American Samoa | AS | 60 |  | Republic of Palau | PW | 70 |
| Federated States of Micronesia | FM | 64 |  | Puerto Rico | PR | 72 |
| Guam | GU | 66 |  | Republic of the Marshall Islands | MH | 68 |
| Commonwealth of the Northern Mariana Islands | MP | 69 |  | U.S. Virgin Islands | VI | 78 |

## **Appendix D**

|  |  |  |
| --- | --- | --- |
| **Drug name** | **Gene name** | **Comments** |
| Isoniazid | *katG* |  |
| Isoniazid and Ethionamide | *inhA* | *InhA* is associated with low level resistance to both isoniazid and ethionamide. Note that ethionamide has another gene associated with resistance, *ethA* (shown below). |
| Isoniazid | *ahpC-oxyR* |  |
| Isoniazid | *fabG1* | Also known as *mabA*. Mutations associated with fabG1 (mabA) have also been reported for resistance to ethionaminde. |
| Rifampin | *rpoB* | Rifampin is among the drug group rifamycins. Rifamycins also include rifapentine and rifabutin. A mutation in the *rpoB* gene does not necessarily confer resistance to all rifamycin drugs. |
| Pyrazinamide | *pncA* |  |
| Ethambutol | *embB* |  |
| Second-line injectables | *rrs* | Second-line injectables include Kanamycin (KAN), Amikacin (AM), Capreomycin (CAP). Note: *rrs* is also associated with streptomycin resistance. *rrs* is also known as 16S rRNA. |
| Kanamycin | *eis* |  |
| Capreomycin | *tlyA* |  |
| Fluoroquinolones | *gyrA* | Examples of fluoroquinolone drugs include Moxifloxacin (MXF), Ofloxacin (OFL), Ciprofloxacin (CIP), and Levofloxacin (LEV) |
| Fluoroquinolones | *gyrB* |
| Ethionamide | *ethA* |  |
| Streptomycin | *rpsL, rrs* |  |
| Bedaquiline | *atpE, rv0678, pepQ (rv2535c)* | p*epQ* is also known as *rv2535c.* Mutations associated with *rv0678* can result in cross resistance with clofazimine. |
| Linezolid | *23S rRNA, rplC, rrl* | *rrl* gene is also known as 23S |
| Clofazimine | *rv0678, pepQ, rv1979c* | Mutations associated with *rv0678* can result in cross resistance with bedaquiline. |
| Delamanid | *fbiA, fbiB, fbiC, ddn, fgd1* |  |

**Anti-TB Drug Names and Genes Associated with Resistance**

## **Appendix E**

**RVCT Molecular (DST) Report**

**Instructions**

The RVCT Molecular DST Reportprovides information on test results for mutations associated with drug resistance. Complete this section for confirmed TB cases that have molecular testing performed for drug resistance. For each patient, report the full test results for the samples that have unique features, such as specimen type (sputum or another anatomic site), test type (sequencing or nonsequencing) or mutation (detected or not detected). There is no need to report test results that differ only by date or laboratory and where all other aspects are identical in regards to specimen type, test type, and/or the results of mutation. For example, if patient X has two sputum specimens collected one week apart and the first is sent to a hospital laboratory and found to have a mutation in *rpoB* by Xpert®, and the second is sent to the state laboratory and found to have the same result by Xpert®, then record only the earlier laboratory report. Enter any test result occurring for the first time, or if repeated, the result or conditions change (for example, a mutation for *rpoB* *nonsequencing* test is performed first, then a mutation for *rpoB sequencing* test is performed two weeks later). Enter as many tests as needed to document possible drug resistance, drug susceptibility, or acquired resistance occurring throughout the patient’s clinical care.

**Gene Name**. The gene name is the name of the gene associated with resistance to an anti-TB drug. The most common gene names associated with anti-TB drug resistance, with their associated drug names, are listed in Appendix D. Indicate the gene name listed on the laboratory report in the appropriate field.

**Collection Date**. The collection date is the date that the specimen (clinical sample) was collected from the patient as it is listed on the laboratory report. Enter the month, day, and year (mm/dd/yyyy) that the sample was collected as reported on the laboratory report. If the day is unknown enter 99 as the default value (e.g. 01/99/2019). Each test result should have a *date specimen collected*.

**Report Date**. The report date is the date that the molecular DST test result was reported by the laboratory. The date is found on the laboratory report as the date the report is released or made available to the requestor. Enter the month, day, and year (mm/dd/yyyy) the test result was made available by the laboratory as shown on the lab report (some labs don’t report this date but most do). If the day is unknown enter 99 as the default value (e.g. 01/99/2019).

**Specimen Type**.The specimen type (Appendix I) is the source of clinical sample or isolate (sputum or other) that has been tested for a mutation associated with drug resistance.

**Results.** Select the results as shown on the laboratory report for the selected gene. If the gene was not tested leave the option blank.

a. Mutation detected

b. Mutation not detected

c. Unknown

There are other items you may see on a laboratory report form. Below are a few definitions associated with mutations.

**Single nucleotide polymorphism (SNP)** - a change in a single nucleotide in the DNA sequence, an A, T, C, or G from what is commonly observed (i.e., wild type). Multiple point mutations can occur within the same locus.

**Deletion** - a mutation that can occur when a single nucleotide or set of nucleotides is removed from a DNA sequence. A deletion can be small (i.e., one to few nucleotides) or large (i.e., a whole segment of the chromosome) and the effect of the deletion on viability of the organism or antibiotic resistance will depend on the location of the deletion and how the deletion affects protein synthesis.

**Insertion** - a mutation that can occur when a single nucleotide or set of nucleotides is inserted within a DNA sequence. An insertion can be small (i.e., one to few nucleotides) or large (i.e., a whole segment of the chromosome).

*NOTE:* Insertions and deletions are often referred to as ***indels***. Also, insertions and deletions can result in what is known as a frameshift mutation (also called frameshift change or FSC). Therefore, if “frameshift” or “FSC” is listed as the result on the laboratory report, mark the gene name, the result of mutation, and the test type. You can record indels in a separate column (see below).

**Nucleic Acid Change**. For each SNP, insert the nucleic acid change associated with the mutation as indicated on the laboratory report. Nucleic acid changes appear only if a mutation has occurred and a sequencing test type was performed.

Please insert the nucleic acid change in *abc>xyz* format, if included in the laboratory report. The *abc* is the 3-letter codon for the NA found in the naturally occurring bacterium, e.g. the nonresistant or sensitive (drug-susceptible) strain of *M. tuberculosis*. The *xyz* is the 3-letter codon for the nucleic acid found in the sample tested. Nucleic acid changes and amino acid changes are specific to the gene where the mutation occurs. A codon is three consecutive nucleotides (consisting of adenosine [A], thymidine [T], cytidine [C], or guanosine [G]) that enables the production of a specific amino acid. If the nucleic acid change is not provided in 3-letter codon format, please enter the information as reflected in the laboratory report (e.g., c>z) or leave blank if not provided.

Certain genes, such as *inhA*, *ahpC-oxyR*, *rrs* and *eis* will typically only have nucleic acid changes (i.e., no amino acid change to report). Nucleic acid changes in this group of genes may appear differently and the location of the mutation on the genome will be added to the nucleic acid change, e.g. ‘*C(-34)G’* for *inhA*, *‘-45 AT insertion’* for *ahpC-oxyR*, ‘*A1410G*’ for *rrs*, or G(-10)A for *eis*.

If no mutation has occurred then no nucleic acid change should be listed on the laboratory report. The examples below show common mutations occurring in drug resistant TB with the nucleic acid and amino acid changes specific to the mutations occurring in the associated genes.

Example: Gene tested — *katG*

Results — mutation detected

Nucleic acid change — AGC>ACC

Amino acid change — Ser315Thr

Example: Gene tested — *rpoB*

Results — mutation detected

Nucleic acid change — TCG>TTG

Amino acid change — Ser531Leu

Example: Gene tested — *inhA*

Results — mutation detected

Nucleic acid change — C-15T *(The position on the genome is -15. The nucleic acid change is from C [cytidine] to T [thymidine])*

Amino acid change — not applicable

**Amino Acid Change**. Indicate the amino acid change associated with the mutation as indicated on the laboratory report. Amino acid changes appear only if a mutation resulting in a substitution has occurred and a sequencing test type was performed. Nucleic acid and amino acid changes do not usually appear on a laboratory report if the test type used was a nonsequencing method.

Amino acid changes are associated with mutations to genes *katG, rpoB, pncA, embB, tlyA, gyrA, gyrB, ethA and rpsL*. If a mutation has not occurred then the amino acid change, as well as a nucleic acid change, should not appear on the laboratory report. The genes *inhA* and *eis* are usually associated with only nucleic acid changes but some research has shown that amino acid changes can occur.

A common amino acid change found in drug resistant TB is the amino acid change for the gene associated with rifampin resistance, *rpoB*, Ser531Leu (or Ser450Leu depending on numbering system used). In this example, 531 refers to the location or position of the codon in the *rpoB* gene and Ser to Leu refers to the change in amino acid (serine to leucine).

The following explains the nomenclature used for reporting amino acid changes, using Ser531Leu as an example:

**Ser531Leu**

**Ser** is the abbreviation for serine, the amino acid found in wild-type *M. tuberculosis.*

**531** refers to the location or position of the codon in the rifampin-resistant determining region (RRDR) of the *rpoB* gene where the mutation occurred.

**Leu** is the abbreviation for leucine, the amino acid substitution found in the resistant *M. tuberculosis.*

This amino acid change indicates there was a mutation in the RRDR of the *rpoB* gene at location **531** resulting in a change of the corresponding amino acid from **serine** to **leucine**.

**Indels.** If a laboratory reports an **in**sertion or a **del**etion (or just simply calls it an “indel”) select the appropriate option.

* 1. Deletion (if a deletion is recorded or noted on the lab report)
  2. Insertion (if a insertion is recorded or noted on the lab report)
  3. “Indel” (if an “indel” is recorded or noted on the lab report)

**Test Type**. Select the test type (method) used for the molecular test as reported on the laboratory report.

a. Nonsequencing Methods: Non-sequencing methods can be real-time PCR, line probe assay, or Xpert® MTB/RIF (Xpert® MTB/RIF applies only to the *rpoB* gene associated with rifampin resistance). Nonsequencing methods do not usually have nucleic acid or amino acid changes reported on the laboratory report form.

b. Sequencing Methods: Pyrosequencing, Sanger sequencing, Next Generation Sequencing (NGS), Targeted-Based Sequencing, Amplicon-Based Sequencing, Whole Genome Sequencing (WGS). Sequencing methods will usually have nucleic acid or amino acid changes recorded on the laboratory report form.

c. Unknown: the testing method was unknown or not indicated on the laboratory report.

**APPENDIX F**

**RVCT Molecular DST Report Examples**

The following examples show how molecular DST results should be recorded on the RVCT according to the variable (item) definitions.

**Example 1**

Laboratory reports contained the following information:

Sputum samples from patient Y collected on 10/25/2017 and 1/6/2018, were sent to state public health laboratory and to CDC, respectively. The first specimen was tested using real-time PCR and found to have mutations in *katG* and *rpoB* and reported to the state TB program on 10/27/2017. The second sputum specimen, collected on 1/6/2018, had mutations *katG, rpoB, pncA, embB, gyrA* and *eis* and **no** mutations in *inhA, rrs*, or *tlyA* using Sanger sequencing performed on an isolate. These results were reported to the state TB program on 4/15/2018.

RVCT Molecular DST Report

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene Name** | **Collection Date**  (mm/dd/yyyy) | **Report Date**  (mm/dd/yyyy) | **Specimen Type**  -sputum  -other (indicate site) | **Results**  -Mutation detected  -Mutation not detected  -Unknown | **Nucleic Acid Change** | **Amino Acid Change** | **Indels** | **Test Type**  -Nonsequencing  -Sequencing  -Unknown |
| *katG* | 10/25/2017 | 10/27/2017 | Sputum | Mutation detected |  |  |  | Non-sequencing |
| *rpoB* | 10/25/2017 | 10/27/2017 | Sputum | Mutation detected |  |  |  | Non-sequencing |
| *katG* | 01/06/2018 | 04/15/2018 | Sputum | Mutation detected | AGC>ACC | Ser315Thr |  | Sequencing |
| *inhA* | 01/06/2018 | 04/15/2018 | Sputum | Mutation not detected |  |  |  | Sequencing |
| *rpoB* | 01/06/2018 | 04/15/2018 | Sputum | Mutation detected | TCG>TTG | Ser531Leu |  | Sequencing |
| *pncA* | 01/06/2018 | 04/15/2018 | Sputum | Mutation detected | ATC>CTC | Ile6Leu |  | Sequencing |
| *embB* | 01/06/2018 | 04/15/2018 | Sputum | Mutation detected | GAC>GCC | Asp354Ala |  | Sequencing |
| *rrs* | 01/06/2018 | 04/15/2018 | Sputum | Mutation not detected |  |  |  | Sequencing |
| *eis* | 01/06/2018 | 04/15/2018 | Sputum | Mutation detected | C-14T |  |  | Sequencing |
| *tlyA* | 01/06/2018 | 04/15/2018 | Sputum | Mutation not detected |  |  |  | Sequencing |
| *gyrA* | 01/06/2018 | 04/15/2018 | Sputum | Mutation detected | GGC>TGC | Gly88Cys |  | Sequencing |
|  |  |  |  |  |  |  |  |  |

*Example 1 -- Notes*

Record both sputum specimen results collected on different dates when the results or test type differ.

In Example 1, the patient had two sputum specimens collected on different dates (10/25/2017 and 1/6/2018) using two different testing methods. The first specimen was sent to the state public health laboratory and was tested using a real-time PCR test which found two mutations, one for *katG* (isoniazid) and one for *rpoB* (rifampin). For the second specimen, collected on 1/6/2016, the laboratory report noted that the testing method was Sanger sequencing. Due to the two different methods used in testing you would want to record both specimens and test results on this patient in the RVCT.

Record the test type for all tests used to test for mutations.

The test type or method used on the first specimen was recorded as real-time PCR on the laboratory report form. Therefore, one would mark “Nonsequencing” as the test type. Since nonsequencing tests do not provide nucleic acid or amino acid changes, one would not mark responses to those variables.

The test type or method used on the second specimen was reported as Sanger sequencing on the laboratory report form. Therefore, one would mark “Sequencing” as the test type and because sequencing tests often provide the nucleic acid and amino acid changes, one would mark responses to those items as well.

When a mutation occurs record the nucleic acid or amino acid changes, as applicable.

This patient’s sputum had mutations using a sequencing method for genes *katG*, *rpoB, pncA, embB, eis,* and *gyrA.* Therefore you would expect to find the nucleic acid or amino acid changes recorded on the laboratory report form. The genes *katG*, *rpoB, pncA, embB* and *gyrA* typically have nucleic acid changes and the corresponding amino acid changes when a mutation occurs. The genes *inhA, rrs*, and *eis* typically have only nucleic acid changes when a mutation occurs and no corresponding amino acid changes.

Leave cells in the table blank when the necessary information not available on the laboratory report form.

**Example 2**

Laboratory reports contained the following information:

Sputum samples from patient X collected on 7/4/2018 and 7/26/2018, were sent to the state public health laboratory. They were tested using real-time PCR and found to have **no** mutations in *katG, inhA*, or *rpoB*. The specimen collected on 7/4/2018 was reported to the state TB program on 11/10/2018. The specimen collected on 7/26/2018 was reported to the state TB program on 11/18/2018 and found to have identical results.

RVCT Molecular DST Report

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene Name** | **Collection Date**  (mm/dd/yyyy) | **Report Date**  (mm/dd/yyyy) | **Specimen Type**  -sputum  -other (indicate site) | **Results**  -Mutation detected  -Mutation not detected  -Unknown | **Nucleic Acid Change** | **Amino Acid Change** | **Indels** | **Test Type**  -Nonsequencing  -Sequencing  -Unknown |
| *katG* | 07/04/2018 | 11/10/2018 | Sputum | Mutation not detected |  |  |  | Nonsequencing |
| *inhA* | 07/04/2018 | 11/10/2018 | Sputum | Mutation not detected |  |  |  | Nonsequencing |
| *rpoB* | 07/04/2018 | 11/10/2018 | Sputum | Mutation not detected |  |  |  | Nonsequencing |

*Example 2-- Notes*

Record only one specimen result when the results and test type do not differ from later specimens.

In Example 2, the patient had two sputum samples sent to the laboratory. In this case it appears that molecular testing was done after the samples were cultured because the reporting dates are delayed. Yet, both specimens had the same results for all genes using the same test type. Therefore, only one set of test results should be recorded on the RVCT. For this situation, choose the earliest sample tested.

**Example 3**

Laboratory reports contained the following information:

A biopsy was collected from the right cervical lymph node from patient W on 11/3/2018 and over a year later, a sputum sample was collected on 12/5/2019. The right neck mass sample was tested at CDC using Sanger sequencing and found mutations in *katG* (nucleic acid change AGC>ACC, amino acid change Ser315Thr), *rpoB* (nucleic acid change CAC>TAC, amino acid change His526Tyr), and *pncA* (nucleic acid change TCC>TCT, amino acid change Ser65Ser). No mutations were detected for *inhA, embB, rrs, eis, tlyA,* or *gyrA*. The results were reported on 12/16/2018.

A sputum sample collected on 12/5/2019 was tested by the state public health laboratory using pyrosequencing and resulted in mutations for *katG* (nucleic acid change AGC>ACC, amino acid change Ser315Thr) and *rpoB* (nucleic acid change TCG>TTG, amino acid change Ser531Leu) and *embB*. The mutation for *embB* was an insertion but no additional information was noted on the laboratory form. The laboratory found no mutations for *inhA, ahpC-oxyR, rrs*, nor *gyrA*. The results were reported on 12/11/2019.

RVCT Molecular DST Report

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene Name** | **Collection Date**  (mm/dd/yyyy) | **Report Date**  (mm/dd/yyyy) | **Specimen Type**  -sputum  -other (indicate site) | **Results**  -Mutation detected  -Mutation not detected  -Unknown | **Nucleic Acid Change** | **Amino Acid Change** | **Indels** | **Test Type**  -Nonsequencing  -Sequencing  -Unknown |
| *katG* | 11/03/2018 | 12/16/2018 | Lymphatic cervical | Mutation detected | AGC>ACC | Ser315Thr |  | Sequencing |
| *inhA* | 11/03/2018 | 12/16/2018 | Lymphatic cervical | Mutation not detected |  |  |  | Sequencing |
| *rpoB* | 11/03/2018 | 12/16/2018 | Lymphatic cervical | Mutation detected | CAC>TAC | His526Tyr |  | Sequencing |
| *embB* | 11/03/2018 | 12/16/2018 | Lymphatic cervical | Mutation not detected |  |  |  | Sequencing |
| *pncA* | 11/03/2018 | 12/16/2018 | Lymphatic cervical | Mutation detected | TCC>TCT | Ser65Ser |  | Sequencing |
| *rrs* | 11/03/2018 | 12/16/2018 | Lymphatic cervical | Mutation not detected |  |  |  | Sequencing |
| *eis* | 11/03/2018 | 12/16/2018 | Lymphatic cervical | Mutation not detected |  |  |  | Sequencing |
| *tlyA* | 11/03/2018 | 12/16/2018 | Lymphatic cervical | Mutation not detected |  |  |  | Sequencing |
| *gyrA* | 11/03/2018 | 12/16/2018 | Lymphatic cervical | Mutation not detected |  |  |  | Sequencing |
| *katG* | 12/05/2019 | 12/11/2019 | Sputum | Mutation detected | AGC>ACC | Ser315Thr |  | Sequencing |
| *inhA* | 12/05/2019 | 12/11/2019 | Sputum | Mutation not detected |  |  |  | Sequencing |
| *ahpC-oxyR* | 12/05/2019 | 12/11/2019 | Sputum | Mutation not detected |  |  |  | Sequencing |
| *rpoB* | 12/05/2019 | 12/11/2019 | Sputum | Mutation detected | TCG>TTG | Ser531Leu |  | Sequencing |
| *embB* | 12/05/2019 | 12/11/2019 | Sputum | Mutation detected |  |  | Insertion | Sequencing |
| *rrs* | 12/05/2019 | 12/11/2019 | Sputum | Mutation not detected |  |  |  | Sequencing |
| *gyrA* | 12/05/2019 | 12/11/2019 | Sputum | Mutation not detected |  |  |  | Sequencing |

*Example 3 – Notes*

Record both specimen results collected when the specimen type, test type, or mutation results differ.

In Example 3, two specimens were collected on 11/3/2018 and 12/5/2019 and both had molecular DST results available. Record the results for both of these specimens because the specimen types differ (right lymph node and sputum).

Notice that between the two samples the genes that were tested and the mutation pattern found was slightly different. The genes *rpoB, embB, pncA, ahpC-oxyR, eis* and *tlyA* were either not tested on both specimens or the results differed. This is another reason to record all results in the RVCT for both specimens.

**Training webinars and other resources**

*Webinars*

* [What about all these mutations? An Introduction to Molecular Biology of TB Drug Resistance](http://cc.readytalk.com/play?id=fcsohd)
* [Mutations Associated with TB Drug Resistance Webinar](http://cc.readytalk.com/play?id=9ylr1k)
* [What's a Doctor to Do? A Clinical Perspective on Mutations Associated with Anti-TB Drug Resistance](http://cc.readytalk.com/play?id=dappaq)


*Other Resources*

Association of Public Health Laboratories


* <https://www.aphl.org/programs/infectious_disease/tuberculosis/> Training modules
  + Molecular Biology 101
  + Molecular Detection and Identification of Mycobacteria
  + Landscape and Language of Molecular Diagnostics for TB Drug Resistance

The Curry Center

* <http://www.currytbcenter.ucsf.edu/trainings/molecular-diagnostics-tuberculosis-what-are-naats-and-how-do-you-use-them>





**Example of Nonsequencing Test Results (Xpert® MTB/RIF)**



**Example of Sequencing Test Results (CDC MDDR)**

**Example of Nonsequencing Test Results (Line Probe Assay)**





**Example of Nonsequencing Test Results (Line Probe Assay) con’t**

## **Appendix G**

|  |  |  |
| --- | --- | --- |
| MDR TB SuPPLEMENTAL SURVEILLANCE FORM  To be completed for all cases treated as MDR TB, regardless of DST results | | |
| 1. History of treatment before current episode with second-line TB drugs for the treatment of TB disease (not LTBI)? [INV1156] | | Yes  No  Unknown |
| **TREATMENT COURSE** | | |
| 1. **Date MDR TB therapy started  for current episode** [INV1157] | Month Day Year  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.** | |
| 1. **Drugs ever used for MDR TB treatment, from MDR start date (select one option for each drug)** | | |

|  |  |
| --- | --- |
| **Drug** [INV1158] | **Length of Time Administered** [INV1159]  (Not Used, <1 Month, ≥1 Month) |
| Isoniazid |  |
| Rifampin |  |
| Pyrazinamide |  |
| Ethambutol |  |
| Streptomycin |  |
| Rifabutin |  |
| Rifapentine |  |
| Amikacin |  |
| Kanamycin |  |
| Capreomycin |  |
| Ethionamide |  |
| Levofloxacin |  |
| Moxifloxacin |  |
| Cycloserine |  |
| Para-Amino Salicylic Acid |  |
| Linezolid |  |
| Bedaquiline |  |
| Delamanid |  |
| Clofazimine |  |
| Pretomanid |  |
| Other (Specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_) |  |

|  |  |
| --- | --- |
| 1. **Date injectable medication was stopped** [INV1160] | Month Day Year  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  **Primary Purpose: Case management. Data are used for evaluating time from TB diagnosis to start of MDR therapy.**  Not applicable |
| 1. **Was surgery performed to treat MDR TB?** [INV1161] | Yes  No Date:\_\_\_\_\_\_\_\_\_\_ [INV1162] |

|  |  |  |
| --- | --- | --- |
| **SIDE EFFECTS** | | |
| **6. Side Effects? [42563-7]** | **Experienced?** [INV1164]  (Yes, No, Unknown) | **When?** [INV1163]  (During Treatment, At End of Treatment, Both) |
| Depression |  |  |
| Suicide Attempt or Ideation |  |  |
| Cardiac Abnormalities |  |  |
| Hearing Loss |  |  |
| Tinnitus |  |  |
| Vestibular Dysfunction |  |  |
| Peripheral Neuropathy |  |  |
| Renal Dysfunction |  |  |
| Vision Change/Loss |  |  |
| Liver Toxicity |  |  |
| Myalgia |  |  |
| Arthralgia |  |  |
| Other (Specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_) |  |  |
| Other (Specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_) |  |  |

**Appendix H**

**Instructions For** **Multidrug-Resistant (MDR) TB**

**Supplemental Form**

To be completed for all patients treated as MDR TB, regardless of DST results

**This will include patients with laboratory evidence (growth-based DST or molecular tests) of MDR TB (resistance to at least isoniazid and rifampin) OR patients with a clinical diagnosis of TB (according to RVCT definitions) who are a known contact to an MDR TB case**. **Note that this form should also be completed for patients with XDR (MDR TB with additional resistance to any fluoroquinolone a second-line injectable drug kanamycin, amikacin, or capreomycin) and pre-XDR TB (MDR TB associated with resistance to fluoroquinolone or a second-line injectable, but not both).**

1. **History of treatment before current episode with second-line TB drugs for the treatment of TB disease (not LTBI)?**

|  |
| --- |
| **Primary Purpose:** Case management and surveillance. Data are used to determine if the patient has been previously exposed to second-line TB drugs. |

|  |  |  |
| --- | --- | --- |
| **Option (*select one*)** | **Description** | **Comment** |
| **Yes** | Patient was treated with second-line TB medications.\* | Often there is no documentation of the patient having been treated in the past if they were treated before arriving in a U.S. reporting area. When documentation is not available, self-report of treatment for a previous episode of MDR TB disease is acceptable.  Do not enter a previous diagnosis of, or treatment course for, latent TB infection (LTBI). |
| **No** | Patient has **not** been treated in the past with second-line TB medications.\* |  |
| **Unknown** | It is **not** **known** whether the patient was previously treated with second-line TB medications.\* |  |

\*Second-line TB drugs include all drugs used to treat TB that is resistant to first-line TB drugs (e.g., capreomycin, ethionamide, cycloserine, ciprofloxacin, amikacin).

1. **Date MDR TB Therapy Started for Current Episode**

|  |
| --- |
| **Primary Purpose:** Programmatic function. Data are used for calculating time from TB diagnosis to start of MDR treatment regimen, overall duration of MDR treatment, and time from MDR treatment start date to culture conversion. |

|  |  |  |
| --- | --- | --- |
|  | **Description** | **Comment** |
| Month, day, year  (e.g., 01/15/2020) | Date the patient first began a drug regimen containing at least 2 second-line drugs. | If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 04/99/1920) or 99/99/1920. If the month, day, and year are unknown, enter 99/99/9999. |

1. **Drugs ever used for MDR TB treatment, from MDR start date (select one option for each drug)**

|  |
| --- |
| **Primary Purpose:** Programmatic function. Data are used for assessing medications that were used as part of a patient’s MDR treatment regimen. |

Select an option for each drug listed. Medications should be recorded as part of the regimen for the current episode beginning with the MDR TB therapy start date. Duration of therapy is a **cumulative** time period and does not have to be consecutively given. This accounts for treatment interruptions and temporary or short stoppages in treatment.

|  |  |
| --- | --- |
| **Drug** [INV1158] | **Length of Time Administered**  (Not Used, <1 Month, ≥1 Month) |
| Isoniazid |  |
| Rifampin |  |
| Pyrazinamide |  |
| Ethambutol |  |
| Streptomycin |  |
| Rifabutin |  |
| Rifapentine |  |
| Amikacin |  |
| Kanamycin |  |
| Capreomycin |  |
| Ethionamide |  |
| Levofloxacin |  |
| Moxifloxacin |  |
| Cycloserine |  |
| Para-Amino Salicylic Acid\* |  |
| Linezolid |  |
| Bedaquiline |  |
| Delamanid |  |
| Clofazimine |  |
| Pretomanid |  |
| Other (Specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_) |  |

**Length of Time Administered**

|  |  |  |
| --- | --- | --- |
| **Option (*select one*)** | **Description** | **Comment** |
| **Not Used** | Drug is/was **not** part of the MDR TB treatment regimen. | If a drug was recommended, but never prescribed or taken by the patient, this category should be marked. |
| **< 1 month** | Drug is/was part of the MDR TB treatment regimen and was taken for less than one month. |  |
| **≥1 month** | Drug is/was part of the MDR TB treatment regimen, and was taken for greater than or equal to one month |  |

1. **Date injectable medication was stopped**

|  |
| --- |
| **Primary purpose:** Programmatic function. Data will be used to determine the duration of injectable medication use in situations where injectables were administered, and estimate the intensive phase in situations where applicable. |

|  |  |  |
| --- | --- | --- |
|  | **Description** | **Comment** |
| Month, day, year  (e.g., 01/15/2020) | Date the patient ended the injectable medication. | If an injectable was started, stopped, and restarted, indicate the last day the injectable was stopped.  If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 04/99/1920) or 99/99/1920. If the month, day, and year are unknown, enter 99/99/9999.  If patient did not receive any injectable medications, mark N/A. |

1. **Was surgery performed to treat MDR TB?**

|  |
| --- |
| **Primary purpose:** Case management and surveillance function. Data will be used to determine the number of patients needing surgery for MDR TB treatment. |

|  |  |  |
| --- | --- | --- |
| **Option (*select one*)** | **Description** | **Comment** |
| **Yes** | Surgery was performed as part of MDR TB treatment for the current episode of MDR TB. | Biopsy done to diagnose MDR TB is not considered surgery to treat MDR TB. However, excisional biopsy for the treatment of extrapulmonary TB is considered surgical treatment for MDR TB. |
| **No** | Surgery was not done for the purpose of MDR TB treatment for the current episode of MDR TB. |  |

**Date of Surgery**

|  |  |  |
| --- | --- | --- |
|  | **Description** | **Comment** |
| Month, day, year  (e.g., 01/15/2020) | Date the patient had surgery for MDR TB. | If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 04/99/1920) or 99/99/1920.  In the month, day, and year are unknown, enter 99/99/9999. |

1. **Side Effects?**

|  |
| --- |
| **Primary purpose:** Case management and surveillance function. Data will be used to determine the nature and number of patients experiencing side effects due to MDR TB treatment. |

Side effects potential related to medications is defined as not existing before MDR TB medication start but having occurred during treatment.

**Side Effects**

|  |  |
| --- | --- |
| **Side Effect** | **Description** |
| **Depression** | * Prolonged feelings of sadness or dejection, or documentation of depression by provider |
| **Suicide Attempt or Ideation** | * Suicidal attempt or ideation (thoughts or attempt to hurt oneself) |
| **Cardiac abnormalities** | * QTc >500 ms (confirmed by repeat ECG or documented “prolonged QTc”) * Clinically significant ventricular arrhythmia |
| **Hearing loss** | * Subjective hearing loss or noticing the need to turn up the volume on phones or TVs * Requiring the needs for a hearing aid or intervention * Adults: If enrolled in Monitoring Program (on a 1, 2, 3, 4, 6 and 8 kHz audiogram): Threshold shift of 15-25 dB averaged at 3 contiguous test frequencies in at least one ear * Pediatric (on a 1, 2, 3, 4, 6 and 8 kHz audiogram): hearing loss sufficient to indicate therapeutic intervention, including hearing aids; threshold shift >20 dB at 3 kHz and above in at least one ear * Speech-language related services indicated |
| **Tinnitus** | * Subjective ringing, buzzing, roaring or clicking sounds in the ears |
| **Vestibular dysfunction** | * Feeling that the world is revolving around the patient (objective vertigo) or the patient is revolving in space (subjective vertigo) * Dizziness or imbalance |
| **Peripheral neuropathy** | * Feeling of tingling, numbness, pressure, cold, and warmth that are experienced in the absence of a stimulus * Usually limited to the extremities |
| **Renal dysfunction** | * Change in baseline renal function or proteinuria |
| **Vision change/loss** | * Can involve one eye or both eyes * Change of baseline of vision acuity or color vision * Optic nerve damage resulting in worsening vision or blindness not present at baseline |
| **Liver toxicity** | * Liver enzyme concentrations exceeding three times the upper limit of normal if associated with symptoms, *or* * Liver enzymes concentrations exceeding five times the upper limit of normal if the patient is asymptomatic |
| **Myalgia** | * Muscle pain |
| **Arthralgia** | * Joint pain. Reports of gout, tendonitis, or tendon rupture may also be marked here |
| **Other** | * Any additional side effects not included above |

**Experienced?**

|  |  |  |
| --- | --- | --- |
| **Option (*select one*)** | **Description** | **Comment** |
| **Yes** | Side effect reported. | Side effects should have been reported by the patient or documented in the medical record.  Side effect that existed prior to MDR TB medication start but exacerbated by MDR TB treatment leading to a MDR TB medication discontinuation should be recorded as **Yes**. |
| **No** | Side effect not reported. |  |
| **Unknown** | It is unknown whether the side effect was reported. |  |

**When?**

|  |  |  |
| --- | --- | --- |
| **Option (*select one*)** | **Description** | **Comment** |
| **During Treatment** | Patient reported side effect only during treatment, i.e., the side effect resolved when treatment was stopped. |  |
| **At the End of Treatment** | Patient reported reportside effect only at the end of treatment, i.e., after the treatment was stopped. |  |
| **Both** | Patient reported side effect during treatment and at the end. |  |

**Example Case Study – “Manas”**

On February 1, 2020, Manas was admitted to the hospital with night sweats, fever, chills and hemoptysis. He said he was treated for TB in India 10 years ago with some medication that turned his urine red but no injectable medication. His sputum smear was positive and he was started on isoniazid, rifampin, pyrazinamide, and ethambutol on February 2, 2020. He remained on this therapy for 3 weeks, until growth-based drug susceptibility testing returned showing the isolate was resistant to isoniazid and rifampin. On February 23, 2020, after consultation with a regional TB expert and hospital infectious disease specialists, he was started on moxifloxacin, ethambutol, pyrazinamide, and linezolid. He was started on capreomycin on March 3, 2020. Because of the cost of capreomycin, he was changed to amikacin April 15, 2020.

The patient developed progressive high-frequency hearing loss, and his amikacin was discontinued June 6, 2020. He was then started on ethionamide on June 8, 2020. He experienced muscle aches, and his moxifloxacin was changed to levofloxacin on November 10, 2020. His muscle aches continued to progress, and his levofloxacin was changed to cycloserine instead on November 20, 2020. In February of 2021 his muscle aches had improved, but he developed numbness and tingling of his fingers and toes. Linezolid was stopped, and he was started on para-amino salicylic acid. He began having joint pains in April of 2021 and his pyrazinamide was discontinued. He finished his treatment on August 10, 2021 on cycloserine, ethambutol, para-amino salicylic acid, and ethionamide. At the last visit, he continued to complain of hearing loss and stable numbness and tingling in his fingers and toes. His muscle and joint pains had resolved.

**See example of the MDR Form filled out based on this case study on the next page.**

|  |  |  |
| --- | --- | --- |
| MDR TB SUPPLEMENTAL SURVEILLANCE FORM  To be completed for all cases treated as MDR TB, regardless of DST results | | |
| 1. **History of treatment before current episode with second-line TB drugs for the treatment of TB disease (not LTBI)?** [INV1156] | | Yes  No  Unknown |
| **TREATMENT COURSE** | | |
| 1. **Date MDR TB therapy started  for current episode** [INV1157] | Month Day Year | |
| 1. **Drugs ever used for MDR TB treatment, from MDR start date (select one option for each drug)**   02 / 23 / 2020 | | |

|  |  |
| --- | --- |
| **Drug** [INV1158] | **Length of Time Administered** [INV1159]  (Not Used, <1 Month, ≥1 Month) |
| Isoniazid | <1 month |
| Rifampin | <1 month |
| Pyrazinamide | > 1month |
| Ethambutol | > 1month |
| Streptomycin | Not used |
| Rifabutin | Not used |
| Rifapentine | Not used |
| Amikacin | > 1month |
| Kanamycin | Not used |
| Capreomycin | > 1month |
| Ethionamide | > 1month |
| Levofloxacin | <1 month |
| Moxifloxacin | > 1month |
| Cycloserine | > 1month |
| Para-Amino Salicylic Acid | > 1month |
| Linezolid | > 1month |
| Bedaquiline | Not used |
| Delamanid | Not used |
| Clofazimine | Not used |
| Pretomanid |  |
| Other (Specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_) |  |

|  |  |
| --- | --- |
| 1. **Date injectable medication was stopped** [INV1160] | Month Day Year  06 / 06 / 2020  Not applicable |
| 1. **Was surgery performed to treat MDR TB?** [INV1161] | Yes  No Date:\_\_\_\_\_\_\_\_\_\_ [INV1162] |

|  |  |  |
| --- | --- | --- |
| **SIDE EFFECTS** | | |
| **Side Effect** [42563-7] | **Experienced?** [INV1164]  (Yes, No, Unknown) | **When?** [INV1163]  (During Treatment, At End of Treatment, Both) |
| Depression | No |  |
| Suicide Attempt or Ideation | No |  |
| Cardiac Abnormalities | No |  |
| Hearing Loss | Yes | Both |
| Tinnitus | No |  |
| Vestibular Dysfunction | No |  |
| Peripheral Neuropathy | Yes | Both |
| Renal Dysfunction | No |  |
| Vision Change/Loss | No |  |
| Liver Toxicity | No |  |
| Myalgia | Yes | During Treatment |
| Arthralgia | Yes | During Treatment |
| Other (Specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_) | No |  |
| Other (Specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_) |  |  |

Appendix I

Anatomic Sites

Site of Disease

| NTSS Concept Name | NTSS Alternate Code | HL7 Concept Code | HL7 Concept Name |
| --- | --- | --- | --- |
| Accessory sinus | AC | 120228005 | Paranasal sinus part (body structure) |
| Adrenal gland | AD | 23451007 | Adrenal structure (body structure) |
| Anus | AN | 53505006 | Anal structure (body structure) |
| Appendix | AP | 66754008 | Appendix structure (body structure) |
| Blood | BL | 87612001 | Blood (substance) |
| Blood vessel | BV | 59820001 | Blood vessel structure (body structure) |
| Bone and/or Joint | BO | 110522009 | Bone and joint (combined site) (body structure) |
| Bone marrow | BM | 14016003 | Bone marrow structure (body structure) |
| Brain | BA | 12738006 | Brain structure (body structure) |
| Breast | BR | 76752008 | Breast structure (body structure) |
| Cardiac valve | CA | 17401000 | Cardiac valve structure (body structure) |
| Colon | CO | 71854001 | Colon structure (body structure) |
| Cranial spinal & peripheral nerve | CR | 25087005 | Structure of nervous system (body structure) |
| Ear and mastoid cells | EA | 110708006 | Middle ear and mastoid cells (body structure) |
| Esophagus | ES | 32849002 | Esophageal structure (body structure) |
| Extrahepatic bile duct | EX | 16014003 | Extrahepatic duct structure (body structure) |
| Eye and ear appendages | EY | PHC4 | Eye and ear appendages |
| Fetus and embryo | FE | C0230999 | Fetus and embryo |
| Gallbladder | GA | 28231008 | Gallbladder structure (body structure) |
| Genitourinary | GU | 21514008 | Structure of genitourinary system (body structure) |
| Heart | HE | 80891009 | Heart structure (body structure) |
| Laryngeal | LX | 110547006 | Epiglottis and larynx (combined site) (body structure) |
| Lip | LP | 48477009 | Lip structure (body structure) |
| Liver | LV | 10200004 | Liver structure (body structure) |
| Lymphatic Axillary | LA | 281777001 | Structure of lymphatic system of axilla (body structure) |
| Lymphatic Cervical | LC | 69831007 | Structure of lymphatic system of neck (body structure) |
| Lymphatic Intrathoracic | LI | 281778006 | Intrathoracic lymphatic structure (body structure) |
| Lymphatic Other | LO | PHC2 | Lymphatic Other |
| Lymphatic Unknown | LU | PHC3 | Lymphatic Unknown |
| Meningeal | ME | 1231004 | Meninges structure (body structure) |
| Mouth | MO | 123851003 | Mouth region structure (body structure) |
| Nasopharynx | NA | 71836000 | Nasopharyngeal structure (body structure) |
| Nose | NO | 45206002 | Nasal structure (body structure) |
| Other | OT | OTH | other |
| Pancreas | PA | 15776009 | Pancreatic structure (body structure) |
| Pericardium | PE | 76848001 | Pericardial structure (body structure) |
| Peritoneal | PT | 83670000 | Peritoneal cavity structure (body structure) |
| Pharynx, oropharynx, and hypopharynx | PH | 54066008 | Pharyngeal structure (body structure) |
| Pituitary gland | PI | 56329008 | Pituitary structure (body structure) |
| Placenta umbilical cord and implantation site | PC | 110973009 | Placenta, umbilical cord and implantation site (combined site) (body structure) |
| Pleura | PL | 3120008 | Pleural membrane structure (body structure) |
| Pulmonary | PU | 39607008 | Lung structure (body structure) |
| Rectum | RE | 34402009 | Rectum structure (body structure) |
| Salivary gland | SA | 385294005 | Salivary gland structure (body structure) |
| Site not Stated | NS | PHC5 | Body Site not Stated |
| Skin and skin appendages | SK | 39937001 | Skin structure (body structure) |
| Small intestine - duodenum | SD | 38848004 | Duodenal structure (body structure) |
| Small intestine - jejunum & ileum | SJ | 110611003 | Jejunum and ileum (combined site) (body structure) |
| Spinal cord | SC | 2748008 | Spinal cord structure (body structure) |
| Spleen | SP | 78961009 | Splenic structure (body structure) |
| Stomach | ST | 69695003 | Stomach structure (body structure) |
| Subcutaneous tissue | SU | 71966008 | Subcutaneous tissue structure (body structure) |
| Thymus | TM | 9875009 | Thymus gland structure (body structure) |
| Thyroid or parathyroid gland(s) | TY | 297261005 | Thyroid and/or parathyroid structures (body structure) |
| Tongue | TO | 21974007 | Tongue structure (body structure) |
| Tonsils and adenoids | TS | 303337002 | Tonsil and adenoid structure (body structure) |
| Tooth gum and supporting structures of the tooth | TH | 362102006 | All teeth, gums and supporting structures (body structure) |
| Trachea | TR | 44567001 | Tracheal structure (body structure) |

Specimen Source Sites

| NTSS Concept Name | NTSS Alternate Code | HL7 Concept Code | HL7 Concept Name |
| --- | --- | --- | --- |
| Accessory sinus | 19 | 120228005 | Paranasal sinus part (body structure) |
| Adrenal gland | 83 | 23451007 | Adrenal structure (body structure) |
| Anus | 55 | 53505006 | Anal structure (body structure) |
| Appendix | 52 | 66754008 | Appendix structure (body structure) |
| Bile and pancreatic fluid | 45 | C0541696 | Bile and pancreatic fluid |
| Blood | 6 | 87612001 | Blood (substance) |
| Blood vessel | 34 | 59820001 | Blood vessel structure (body structure) |
| Bone | 8 | 272673000 | Bone structure (body structure) |
| Bone marrow | 4 | 14016003 | Bone marrow structure (body structure) |
| Brain | 88 | 12738006 | Brain structure (body structure) |
| Breast | 2 | 76752008 | Breast structure (body structure) |
| Bronchial fluid | 28 | 258446004 | Bronchial fluid sample (specimen) |
| Bronchiole | 24 | 55214000 | Bronchiole structure (body structure) |
| Bronchus | 23 | 955009 | Bronchial structure (body structure) |
| Cardiac valve | 32 | 17401000 | Cardiac valve structure (body structure) |
| Cervix | 74 | 71252005 | Cervix uteri structure (body structure) |
| Colon | 53 | 71854001 | Colon structure (body structure) |
| Cranial spinal & periph nerve | 90 | 25087005 | Structure of nervous system (body structure) |
| CSF (cerebrospinal fluid) | 86 | 65216001 | Cerebrospinal fluid (substance) |
| Ear and mastoid cells | 92 | 110708006 | Middle ear and mastoid cells (body structure) |
| Endometrium | 75 | 2739003 | Endometrial structure (body structure) |
| Epididymis vas deferens spermatic cord and scrotum | 68 | 110887005 | Epididymis, vas deferens, spermatic cord and scrotum (combined site) (body structure) |
| Epiglottis and larynx | 21 | 110547006 | Epiglottis and larynx (combined site) (body structure) |
| Esophagus | 48 | 32849002 | Esophageal structure (body structure) |
| Extrahepatic bile duct | 42 | 16014003 | Extrahepatic duct structure (body structure) |
| Eye and ear appendages | 91 | PHC4 | Eye and ear appendages |
| Fallopian tube broad ligament parametrium and paraovarian region | 77 | 110850002 | Fallopian tube, broad ligament, parametrium and parovarian region (combined site) (body structure) |
| Female genital fluids | 79 | 50473004 | Female genital fluid (substance) |
| Fetus and embryo | 81 | C0230999 | Fetus and embryo |
| Gallbladder | 41 | 28231008 | Gallbladder structure (body structure) |
| Gastric aspirate | 56 | 168137004 | Gastric aspirate sample (specimen) |
| Gastrointestinal contents (feces) | 57 | 39477002 | Feces (substance) |
| Heart | 31 | 80891009 | Heart structure (body structure) |
| Joints (synovial tissue) | 16 | 88928006 | Structure of synovial tissue of joint (body structure) |
| Kidney | 60 | 64033007 | Kidney structure (body structure) |
| Ligament and fascia | 15 | 91684004 | Structure of ligament AND/OR fascia (body structure) |
| Lip | 36 | 48477009 | Lip structure (body structure) |
| Liver | 40 | 10200004 | Liver structure (body structure) |
| Lung | 25 | 39607008 | Lung structure (body structure) |
| Lymph node | 7 | 59441001 | Structure of lymph node (body structure) |
| Male genital fluids | 70 | 23378005 | Male genital fluid (substance) |
| Meninges dural sinus choroid plexus | 87 | PHC8 | Meninges, dural sinus, choroid plexus |
| Milk | 3 | 226789007 | Breast milk (substance) |
| Mouth | 35 | 123851003 | Mouth region structure (body structure) |
| Multiple Sites | 95 | PHC6 | Multiple Body Sites |
| Myometrium | 76 | 27232003 | Myometrial structure (body structure) |
| Nasopharynx | 20 | 71836000 | Nasopharyngeal structure (body structure) |
| Nose | 18 | 45206002 | Nasal structure (body structure) |
| Omentum and peritoneum | 58 | PHC7 | Omentum and peritoneum |
| Other | 94 | OTH | Other anatomic site |
| Ovary | 78 | 15497006 | Ovarian structure (body structure) |
| Pancreas | 43 | 15776009 | Pancreatic structure (body structure) |
| Penis | 65 | 18911002 | Penile structure (body structure) |
| Pericardial fluid | 33 | 34429004 | Pericardial fluid (substance) |
| Pericardium | 30 | 76848001 | Pericardial structure (body structure) |
| Peritoneal fluid | 59 | 409614007 | Peritoneal fluid (substance) |
| Pharynx oropharynx and hypopharynx | 46 | 54066008 | Pharyngeal structure (body structure) |
| Pituitary gland | 82 | 56329008 | Pituitary structure (body structure) |
| Placenta umbilical cord and implantation site | 80 | 110973009 | Placenta, umbilical cord and implantation site (combined site) (body structure) |
| Pleura | 26 | 3120008 | Pleural membrane structure (body structure) |
| Pleural fluid | 29 | 2778004 | Pleural fluid (substance) |
| Prostate and seminal vesicle | 66 | 110651000 | Prostate and seminal vesicle (combined site) (body structure) |
| Pus | 93 | 11311000 | Pus (substance) |
| Rectum | 54 | 34402009 | Rectum structure (body structure) |
| Renal pelvis | 61 | 25990002 | Renal pelvis structure (body structure) |
| Saliva | 44 | 256897009 | Saliva (substance) |
| Salivary gland | 39 | 385294005 | Salivary gland structure (body structure) |
| Skeletal system (bones of head rib cage and vertebral column) | 9 | PHC12 | Skeletal system - Bones of head, rib cage and vertebral column |
| Skeletal system (bones of shoulder girdle pelvis and extremities) | 10 | PHC11 | Skeletal system - Bones of shoulder, girdle, pelvis and extremities |
| Skin and skin appendages | 0 | 39937001 | Skin structure (body structure) |
| Small intestine - duodenum | 50 | 38848004 | Duodenal structure (body structure) |
| Small intestine - jejunum & ileum | 51 | 110611003 | Jejunum and ileum (combined site) (body structure) |
| Soft tissue | 11 | 181607009 | Soft tissue (navigational concept) |
| Soft tissue (muscles of head neck mouth and upper extremity) | 12 | PHC10 | Soft tissue - Muscles of head, neck, mouth and upper extremity |
| Soft tissue (muscles of trunk perineum and lower extremity) | 13 | PHC9 | Soft tissue - Muscles of trunk, perineum and lower extremity |
| Spinal cord | 89 | 2748008 | Spinal cord structure (body structure) |
| Spleen | 5 | 78961009 | Splenic structure (body structure) |
| Sputum | 96 | 119334006 | Sputum specimen (specimen) |
| Stomach | 49 | 69695003 | Stomach structure (body structure) |
| Subcutaneous tissue | 1 | 71966008 | Subcutaneous tissue structure (body structure) |
| Synovial fluid | 17 | 6085005 | Synovial fluid (substance) |
| Tendon and tendon sheath | 14 | 59863003 | Tendon and/or tendon sheath structure (body structure) |
| Testis | 67 | 40689003 | Testis structure (body structure) |
| Thymus | 85 | 9875009 | Thymus gland structure (body structure) |
| Thyroid or parathyroid gland(s) | 84 | 297261005 | Thyroid and/or parathyroid structures (body structure) |
| Tongue | 37 | 21974007 | Tongue structure (body structure) |
| Tonsils and adenoids | 47 | 303337002 | Tonsil and adenoid structure (body structure) |
| Tooth gum and supporting structures of the tooth | 38 | 362102006 | All teeth, gums and supporting structures (body structure) |
| Trachea | 22 | 44567001 | Tracheal structure (body structure) |
| Unknown | 99 | UNK | unknown |
| Upper respiratory fluids | 27 | 72869002 | Upper respiratory fluids (substance) |
| Ureter | 62 | 87953007 | Ureteric structure (body structure) |
| Urethra | 64 | 13648007 | Urethral structure (body structure) |
| Urinary bladder | 63 | 89837001 | Urinary bladder structure (body structure) |
| Urine | 69 | 78014005 | Urine (substance) |
| Uterus | 73 | 35039007 | Uterine structure (body structure) |
| Vagina | 72 | 76784001 | Vaginal structure (body structure) |
| Vulva labia clitoris and Bartholin's gland | 71 | 110888000 | Vulva, labia, clitoris and Bartholin's gland (combined site) (body structure) |

## **Appendix J**

**Glossary**

|  |  |
| --- | --- |
| **Term** | **Definition** |
| **Acid-fast bacilli (AFB)** | Microorganisms that when stained, retain color even after they have been washed in an acid solution; may be detected under a microscope in a stained smear. |
| **Active case finding** | Looking for undiagnosed cases by screening a population. |
| **Adherence to treatment** | Following the recommended course of treatment by taking all the prescribed medications for the entire length of time necessary. |
| **Adverse effect** | Negative side effect resulting from the use of a drug (for example, hepatitis, nausea, rash). |
| **Bronchoscopy** | A procedure used to obtain pulmonary secretions or lung tissue with an instrument called a bronchoscope. |
| **Case management** | A system in which a specific health department employee is assigned primary responsibility for the patient, systematic regular review of patient progress is conducted, and plans are made to address any barriers to adherence. |
| **Case rate** | The number of cases that occur during a certain time period, divided by the size of the population during that time period; the case rate is often expressed in terms of a population size of 100,000 persons. |
| **Case reporting** | Informing the state or local health department when a new possible or confirmed case (an occurrence) of TB disease has been diagnosed. |
| **Cavity** | A hollow space within the lung, visible on a chest x-ray or CT scan. |
| **Clinical evaluation** | An evaluation done to find out whether a patient has symptoms of TB disease or is responding to treatment; also done to check for adverse reaction to TB medications. |
| **Clinician** | A physician, physician’s assistant, or nurse/nurse practitioner. |
| **Congregate setting** | A setting in which a group of usually unrelated persons reside in close physical proximity. These settings may include long-term care facilities, assisted living facilities, correctional facilities, or homeless shelters (see residential facilities). |
| **Contact investigation** | A procedure for interviewing a person who has TB disease to determine who may have been exposed to TB. People who have been exposed to a TB patient are located and tested for TB infection and TB disease, and treated if indicated. |
| **Contacts** | People exposed to someone with TB disease, generally including family members, roommates or housemates, close friends, coworkers, classmates, and others. |
| **Country of birth** | The country where a person was born. |
| **Culture** | To grow organisms in or on media (substances containing nutrients) so that they can be identified. |
| **Daily regimen** | A treatment schedule in which the patient takes a dose of each prescribed medication every day. |
| **Diabetes mellitus** | A disease in which the body’s ability to produce or respond to the hormone insulin is impaired, resulting in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood and urine. See detailed diagnostic criteria for diabetes elsewhere in this manual. |
| **Diagnostic evaluation** | An evaluation used to diagnose TB disease; includes a medical history, a chest x-ray, the collection of specimens for bacteriologic examination, and possibly a tuberculin skin test or an interferon-gamma release assay. |
| **Directly observed therapy (DOT)** | Where a designated healthcare worker watches the TB patient swallow each dose of the prescribed drugs. |
| **Drug susceptibility test** | A laboratory method for detecting drug-resistant microorganisms. |
| **Drug-resistant TB** | TB caused by organisms that are able to grow in the presence of a particular drug; TB that is resistant to at least one first-line antituberculosis drug. |
| **End-stage renal disease (ESRD)** | A condition when chronic kidney failure has progressed to the point where kidney function is less than 10% of normal; requires dialysis or transplantation; also known as stage 5 chronic kidney disease. The most common cause of ESRD in the United States is diabetes. |
| **Epidemiologically linked** | The patient has had contact with one or more persons who have/had TB disease or have been exposed to a point source of infection (i.e., a single source of infection, such as an event or location where one or more patients had a confirmed case of TB disease).  Transmission of  *M. tuberculosis* complex by the usual modes of transmission, e.g., aerosol, is plausible.  A case may be considered epidemiologically linked to a laboratory-confirmed case if at least one case in the chain of transmission is laboratory confirmed. |
| **Ethambutol (EMB)** | A drug used to treat TB disease; may cause vision problems. Ethambutol should be used cautiously in children who are too young to be monitored for changes in their vision. |
| **Extrapulmonary TB** | TB disease that occurs in places other than the lungs, such as the lymph nodes, the pleura, the brain, the kidneys, or the bones; most types of extrapulmonary TB are not infectious. |
| **First-line TB drugs** | The initial drugs typically used for treating TB disease. Includes isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB). |
| **HIV** | Human immunodeficiency virus, the virus that causes AIDS. |
| **Immunosuppressive therapy** | Therapy that suppresses or weakens the immune system. |
| **Interferon-gamma  (IFN-γ)** | Protein that is normally produced by the body in response to infection. |
| **Interferon-gamma release assay (IGRA)** | A type of blood test that measures a person’s immune reactivity to *M. tuberculosis* by measuring release of IFN-γ. In the U.S., QuantiFERON®-TB Gold, QuantiFERON®-TB Gold In-Tube, QuantiFERON®-TB Plus and T-SPOT®.TB are currently available IGRAs. |
| **Isolate** | A sample from a specimen that was identified as a certain organism such as *M. tuberculosis* complex. |
| **Isoniazid (INH)** | A drug that is used for treating LTBI and one of the drugs used to treat TB disease; although relatively safe, it may cause hepatitis and other severe adverse reaction in some patients. |
| **Latent TB infection (LTBI)** | Refers to the condition when a person is infected with tubercle bacilli, but TB disease has not developed. Persons with LTBI do not have TB disease symptoms and they cannot spread TB to others. Persons with LTBI usually have a positive result to the Mantoux tuberculin skin test or an interferon-gamma release assay. |
| **LTBI treatment** | Medication that is given to people who have latent TB infection to prevent them from developing TB disease. |
| **Mantoux tuberculin skin test (TST)** | A method of testing for TB infection; a needle and syringe are used to inject 0.1 ml of 5 tuberculin units of liquid tuberculin between the layers of the skin (intradermally), usually on the forearm; the reaction to this test, sometimes a palpable swollen area (induration), is measured 48 to 72 hours after TST placement and is interpreted as positive or negative depending on the size of the induration in millimeters (mm) and the patient’s risk factors for TB. |
| **Miliary TB** | Miliary TB is a serious type of tuberculosis infection. It is a histological or radiologic finding, rather than a site of disease. It appears on radiographs as a great number of small, well-defined nodules that look like millet seeds scattered throughout the lungs, hence the name “miliary.” |
| **Multidrug-resistant TB (MDR TB)** | Resistant to at least the drugs isoniazid and rifampin; MDR TB is more difficult to treat than drug-susceptible TB. |
| ***Mycobacterium tuberculosis*** | One of the organisms causing TB in humans, and sometimes called the tubercle bacillus; belongs to a group of bacteria called mycobacteria. |
| ***Mycobacterium tuberculosis* complex** | A group of closely related mycobacteria that can cause TB (e.g., *M. tuberculosis, M. bovis*, and *M. africanum*). Most TB in the United States is caused by *M. tuberculosis*. |
| **NEDSS/HL-7** | National Electronic Disease Surveillance System (NEDSS)/Health Level 7 (HL-7) |
| **Non-U.S.–born persons** | Persons who are not eligible for U.S. citizenship at birth, regardless of the actual country of birth (formerly called “foreign-born”). |
| **Nucleic acid amplification (NAA)** | Atechnique that amplifies (copies) DNA or RNA segments, in order to directly identify microorganisms in clinical specimens. |
| **Possible** | A person for whom there is a high index of suspicion for active TB (e.g., a known contact to an active TB case or to a person with signs or symptoms consistent with TB) who is currently under evaluation for TB disease. Also referred to as “Suspected” in some surveillance data systems. |
| **Pulmonary TB** | TB disease that occurs in the lungs, typically causing a cough and an abnormal chest x-ray. Pulmonary TB is usually infectious if untreated. Most TB cases reported in the United States are pulmonary TB. |
| **Pyridoxine** | Another name for vitamin B6; it is given to prevent peripheral neuropathy; should always be given to pregnant and breastfeeding women on isoniazid. |
| **Recurrence** | A patient who has either a   * Negative culture result while receiving anti-TB therapy, but at some point after therapy is completed, either the culture result becomes positive for *M. tuberculosis* again or the patient has clinical or radiologic deterioration that is consistent with TB disease, **or** * Negative smear and culture result (e.g., clinical case) at diagnosis and while receiving anti-TB therapy, but at some point after therapy is completed, either the patient has a culture result that is positive for *M. tuberculosis* or has clinical or radiologic deterioration that is consistent with TB disease. |
| **Rifabutin** | A drug used to treat TB disease; used as a substitute for rifampin (RIF) in the treatment of all forms of TB. |
| **Rifampin** | A drug used to treat TB disease; also used for LTBI treatment. |
| **Rifapentine** | A drug used to treat TB disease and LTBI; used once weekly with isoniazid for twelve weeks during the continuation phase with selected HIV-negative patients. |
| **Second-line TB drugs** | Drugs used to treat TB that is resistant to first-line TB drugs (e.g., capreomycin, ethionamide, cycloserine, ciprofloxacin, amikacin). |
| **Smear** | A specimen that has been smeared onto a glass slide, stained, washed in an acid solution, and then placed under the microscope for examination; used to detect acid-fast bacilli in a specimen. |
| **Specimen** | A sample collected from a person for testing. |
| **Sputum** | Phlegm from deep in the lungs, collected in a sterile container for processing and examination. |
| **Susceptibility** | An organism’s ability to be killed by a particular drug. |
| **TB disease** | An illness, caused by bacteria called *Mycobacterium tuberculosis*, in which tuberculosis (TB) bacteria are multiplying and attacking parts of the body, most commonly the lungs. A person with TB disease is capable of spreading the disease to others if the TB bacteria are active in the lungs or throat. The symptoms of TB disease include weakness, weight loss, fever, no appetite, chills, and sweating at night. Other symptoms may include a bad cough, pain in the chest, and coughing up blood. |
| **XDR TB** | Extensively Drug-Resistant TB. The occurrence of TB in persons whose *M. tuberculosis* isolates are resistant to isoniazid and rifampin, plus resistant to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). |

1. Most laboratories use tests that do not routinely distinguish *Mycobacterium tuberculosis* from very closely related species. These laboratories report culture results as being positive or negative for “*Mycobacterium tuberculosis* complex” (MTC). Disease caused by any member of the MTC meets the TB surveillance case definition **except** for the BCG strain of *M. bovis*, which should not be reported as TB, even if there is no history of BCG vaccination or cancer immunotherapy. [↑](#footnote-ref-2)
2. U.S. Citizenship and Immigration Services. USCIS.gov Glossary. <https://www.uscis.gov/tools/glossary?topic_id=b#alpha-listing>. Accessed on October 29, 2019. [↑](#footnote-ref-3)